GOName,GOID,DiseaseName,DiseaseID,InferenceChemicalQty,InferenceChemicalNames,InferenceGeneQty,InferenceGeneSymbols
14-3-3 protein binding,GO:0071889,Parkinson Disease,MESH:D010300,0,,1,DDIT4
17-beta-hydroxysteroid dehydrogenase (NADP+) activity,GO:0072582,Parkinson Disease,MESH:D010300,1,Eicosapentaenoic Acid,0,
17-beta-hydroxysteroid dehydrogenase (NADP+) activity,GO:0072582,Parkinsonian Disorders,MESH:D020734,1,Docosahexaenoic Acids,0,
1-alkyl-2-acetylglycerophosphocholine esterase activity,GO:0003847,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
1-phosphatidylinositol-3-kinase activity,GO:0016303,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
1-phosphatidylinositol-3-kinase activity,GO:0016303,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
2-oxoglutarate-dependent dioxygenase activity,GO:0016706,Parkinsonian Disorders,MESH:D020734,0,,1,PRL
"3',5'-cyclic-AMP phosphodiesterase activity",GO:0004115,Parkinson Disease,MESH:D010300,1,Atrazine,0,
"3',5'-cyclic-AMP phosphodiesterase activity",GO:0004115,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
"3',5'-cyclic-AMP phosphodiesterase activity",GO:0004115,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
3'-5' exonuclease activity,GO:0008408,Parkinsonian Disorders,MESH:D020734,0,,1,POLG
3-beta-hydroxy-delta5-steroid dehydrogenase activity,GO:0003854,"Parkinson Disease, Secondary",MESH:D010302,1,Flurbiprofen,0,
3-beta-hydroxy-delta5-steroid dehydrogenase activity,GO:0003854,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Indomethacin,0,
3beta-hydroxysteroid dehydrogenase activity,GO:0102727,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
3beta-hydroxysteroid dehydrogenase activity,GO:0102727,Parkinsonian Disorders,MESH:D020734,4,Chlorpromazine|coenzyme Q10|cypermethrin|mancozeb,0,
3-chloroallyl aldehyde dehydrogenase activity,GO:0004028,Parkinsonian Disorders,MESH:D020734,0,,2,ALDH1A1|ALDH1A2
3-deoxyglucosone dehydrogenase activity,GO:0106373,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A1
3-phosphoinositide-dependent protein kinase activity,GO:0004676,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
3-phosphoinositide-dependent protein kinase activity,GO:0004676,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
3-phosphoinositide-dependent protein kinase activity,GO:0004676,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
3-phosphoinositide-dependent protein kinase activity,GO:0004676,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
3-phosphoinositide-dependent protein kinase activity,GO:0004676,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
3-phosphoinositide-dependent protein kinase binding,GO:0043423,Parkinson Disease,MESH:D010300,0,,1,INSR
4-nitrophenol 2-monooxygenase activity,GO:0018601,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
5.8S rRNA binding,GO:1990932,Parkinson Disease,MESH:D010300,0,,1,RPL6
5-aminolevulinate synthase activity,GO:0003870,Parkinson Disease,MESH:D010300,1,Trichloroethylene,0,
5-aminolevulinate synthase activity,GO:0003870,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
5'-deoxyribose-5-phosphate lyase activity,GO:0051575,Parkinsonian Disorders,MESH:D020734,0,,1,POLG
5-hydroxy-L-tryptophan decarboxylase activity,GO:0036467,Parkinson Disease,MESH:D010300,0,,1,DDC
5-hydroxy-L-tryptophan decarboxylase activity,GO:0036467,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
5'-nucleotidase activity,GO:0008253,"Parkinson Disease, Secondary",MESH:D010302,4,Benzo(a)pyrene|geraniol|Silymarin|thymoquinone,0,
5'-nucleotidase activity,GO:0008253,Parkinsonian Disorders,MESH:D020734,2,geraniol|Silymarin,0,
6-phosphofructo-2-kinase activity,GO:0003873,Parkinson Disease,MESH:D010300,1,Lithium Carbonate,0,
6-phosphofructo-2-kinase activity,GO:0003873,"Parkinson Disease, Secondary",MESH:D010302,1,Lithium Carbonate,0,
6-phosphofructokinase activity,GO:0003872,Parkinson Disease,MESH:D010300,1,Lead,0,
ABC-type oligopeptide transporter activity,GO:0015421,Parkinson Disease,MESH:D010300,0,,1,ABCB1
ABC-type oligopeptide transporter activity,GO:0015421,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
ABC-type polyamine transporter activity,GO:0015417,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
ABC-type polyamine transporter activity,GO:0015417,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
ABC-type polyamine transporter activity,GO:0015417,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
ABC-type transporter activity,GO:0140359,Parkinson Disease,MESH:D010300,0,,2,ABCB1|RAB32
ABC-type transporter activity,GO:0140359,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
ABC-type xenobiotic transporter activity,GO:0008559,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Endosulfan,1,ABCB1
ABC-type xenobiotic transporter activity,GO:0008559,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,1,ABCB1
ABC-type xenobiotic transporter activity,GO:0008559,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
acetylcholine-gated monoatomic cation-selective channel activity,GO:0022848,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
acetylcholinesterase activity,GO:0003990,Parkinson Disease,MESH:D010300,14,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Aluminum|Chlorpyrifos|Hexachlorocyclohexane|Melatonin|Organophosphates|Particulate Matter|Pesticides|Reserpine|Rivastigmine|Rotenone|Vehicle Emissions|Water Pollutants, Chemical",0,
acetylcholinesterase activity,GO:0003990,"Parkinson Disease, Secondary",MESH:D010302,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Melatonin|Pesticides|Reserpine|Rotenone",1,BCHE
acetylcholinesterase activity,GO:0003990,Parkinsonian Disorders,MESH:D020734,9,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|coenzyme Q10|Melatonin|Particulate Matter|Plant Extracts|Reserpine|Rivastigmine|Rotenone",0,
acetyl-CoA carboxylase activity,GO:0003989,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
acetyl-CoA carboxylase activity,GO:0003989,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
[acetyl-CoA carboxylase] kinase activity,GO:0050405,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
[acetyl-CoA carboxylase] kinase activity,GO:0050405,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
acidic amino acid transmembrane transporter activity,GO:0015172,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
acid phosphatase activity,GO:0003993,Parkinson Disease,MESH:D010300,4,Chlorpyrifos|Estradiol|Iron|Lead,0,
acid phosphatase activity,GO:0003993,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Resveratrol|thymoquinone,0,
acid phosphatase activity,GO:0003993,Parkinsonian Disorders,MESH:D020734,5,Cadmium|Curcumin|manganese chloride|Plant Extracts|Resveratrol,0,
aconitate hydratase activity,GO:0003994,Parkinson Disease,MESH:D010300,3,Paraquat|Selegiline|Zinc,0,
aconitate hydratase activity,GO:0003994,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
aconitate hydratase activity,GO:0003994,Parkinsonian Disorders,MESH:D020734,2,Paraquat|Selegiline,0,
actin binding,GO:0003779,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
actin binding,GO:0003779,Parkinson Disease,MESH:D010300,0,,6,KST|LRRK2|MAP2|MAPT|PRKN|SNCA
actin binding,GO:0003779,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
actin binding,GO:0003779,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
actin binding,GO:0003779,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
actin binding,GO:0003779,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
actin binding,GO:0003779,"Parkinson Disease, Secondary",MESH:D010302,0,,3,NOS2|PRKN|SNCA
actin binding,GO:0003779,Parkinsonian Disorders,MESH:D020734,0,,4,LRRK2|MAPT|PRKN|SNCA
actin filament binding,GO:0051015,Parkinson Disease,MESH:D010300,0,,3,AIF1|KST|PRM
actin filament binding,GO:0051015,Parkinsonian Disorders,MESH:D020734,1,Procaine,0,
actinin binding,GO:0042805,Parkinson Disease,MESH:D010300,0,,1,MLP60A
actin lateral binding,GO:0003786,Parkinson Disease,MESH:D010300,0,,1,KST
active monoatomic ion transmembrane transporter activity,GO:0022853,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
acyl-L-homoserine-lactone lactonohydrolase activity,GO:0102007,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PON1
"acyltransferase activity, transferring groups other than amino-acyl groups",GO:0016747,Parkinson Disease,MESH:D010300,0,,1,RDGA
adenosine deaminase activity,GO:0004000,Parkinson Disease,MESH:D010300,1,Zinc,1,ADARB2
adenylate cyclase inhibitor activity,GO:0010855,"Parkinson Disease, Secondary",MESH:D010302,0,,1,RGS2
adenylate kinase activity,GO:0004017,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,0,
adenyl-nucleotide exchange factor activity,GO:0000774,Parkinson Disease,MESH:D010300,0,,1,BAG5
ADP binding,GO:0043531,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
ADP-D-ribose binding,GO:0072570,Parkinson Disease,MESH:D010300,0,,1,TRPM2
ADP phosphatase activity,GO:0043262,Parkinson Disease,MESH:D010300,1,Caffeine,0,
ADP-ribose diphosphatase activity,GO:0047631,Parkinson Disease,MESH:D010300,0,,1,TRPM2
adrenergic receptor activity,GO:0004935,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
adrenergic receptor activity,GO:0004935,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
adrenergic receptor activity,GO:0004935,Parkinsonian Disorders,MESH:D020734,0,,1,DOP1R2
alanine:sodium symporter activity,GO:0015655,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
alcohol dehydrogenase (NAD+) activity,GO:0004022,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ADH1C
alcohol dehydrogenase (NAD+) activity,GO:0004022,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
aldehyde dehydrogenase (NAD+) activity,GO:0004029,Parkinson Disease,MESH:D010300,0,,1,ALDH2
aldehyde dehydrogenase (NAD+) activity,GO:0004029,Parkinsonian Disorders,MESH:D020734,1,Disulfiram,2,ALDH1A1|ALDH1A2
aldehyde dehydrogenase [NAD(P)+] activity,GO:0004030,Parkinson Disease,MESH:D010300,5,Benomyl|Dieldrin|Maneb|triflumizol|Ziram,1,ALDH2
aldehyde dehydrogenase [NAD(P)+] activity,GO:0004030,"Parkinson Disease, Secondary",MESH:D010302,3,Dieldrin|Maneb|Ziram,0,
aldehyde dehydrogenase [NAD(P)+] activity,GO:0004030,Parkinsonian Disorders,MESH:D020734,2,Maneb|Plant Extracts,0,
alditol:NADP+ 1-oxidoreductase activity,GO:0004032,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
alditol:NADP+ 1-oxidoreductase activity,GO:0004032,Parkinsonian Disorders,MESH:D020734,2,Phenol|Valproic Acid,0,
alkaline phosphatase activity,GO:0004035,Parkinson Disease,MESH:D010300,14,Carbon Tetrachloride|Chlorpyrifos|Coffee|Endosulfan|Estradiol|Homocysteine|Lead|Lipopolysaccharides|Methomyl|pendimethalin|Pioglitazone|Sirolimus|Tea|Zinc,0,
alkaline phosphatase activity,GO:0004035,"Parkinson Disease, Secondary",MESH:D010302,10,Benzo(a)pyrene|Doxorubicin|Methotrexate|Nicotine|Paroxetine|Resveratrol|Silymarin|thymoquinone|Valproic Acid|Vincristine,0,
alkaline phosphatase activity,GO:0004035,Parkinsonian Disorders,MESH:D020734,15,Amphotericin B|baicalin|Cadmium|coenzyme Q10|Coffee|Curcumin|cypermethrin|Lipopolysaccharides|manganese chloride|Paroxetine|Plant Extracts|Resveratrol|Silymarin|Valproic Acid|Zidovudine,0,
alkane 1-monooxygenase activity,GO:0018685,Parkinson Disease,MESH:D010300,1,Dicamba,0,
alpha1-adrenergic receptor activity,GO:0004937,Parkinsonian Disorders,MESH:D020734,0,,1,DOP1R2
alpha-2A adrenergic receptor binding,GO:0031694,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
alpha-amylase activity,GO:0004556,Parkinson Disease,MESH:D010300,1,Ditiocarb,0,
alpha-amylase activity,GO:0004556,"Parkinson Disease, Secondary",MESH:D010302,2,Ditiocarb|Resveratrol,0,
alpha-amylase activity,GO:0004556,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Resveratrol,0,
alpha-mannosidase activity,GO:0004559,Parkinsonian Disorders,MESH:D020734,1,Plant Preparations,0,
alpha-tubulin binding,GO:0043014,Parkinson Disease,MESH:D010300,0,,2,PPARGC1A|SNCA
alpha-tubulin binding,GO:0043014,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
alpha-tubulin binding,GO:0043014,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
alpha-tubulin binding,GO:0043014,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
alpha-tubulin binding,GO:0043014,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
amine binding,GO:0043176,Parkinson Disease,MESH:D010300,0,,1,SLC6A3
amine binding,GO:0043176,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
amine transmembrane transporter activity,GO:0005275,Parkinson Disease,MESH:D010300,0,,1,SLC18A2
amine transmembrane transporter activity,GO:0005275,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SLC18A2
amine transmembrane transporter activity,GO:0005275,Parkinsonian Disorders,MESH:D020734,0,,1,SLC18A2
amino acid binding,GO:0016597,Parkinson Disease,MESH:D010300,0,,2,DDC|TH
amino acid binding,GO:0016597,Parkinsonian Disorders,MESH:D020734,0,,2,DDC|TH
amino acid:sodium symporter activity,GO:0005283,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
amino acid transmembrane transporter activity,GO:0015171,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
aminobutyraldehyde dehydrogenase activity,GO:0019145,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A1
aminopeptidase activity,GO:0004177,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Zinc,0,
aminopeptidase activity,GO:0004177,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
aminopeptidase activity,GO:0004177,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
AMP-activated protein kinase activity,GO:0004679,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
AMP-activated protein kinase activity,GO:0004679,Parkinson Disease,MESH:D010300,7,Caffeine|Carbon Disulfide|Lipopolysaccharides|Oxidopamine|Permethrin|Rotenone|Soot,3,GAK|LRRK2|PINK1
AMP-activated protein kinase activity,GO:0004679,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
AMP-activated protein kinase activity,GO:0004679,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
AMP-activated protein kinase activity,GO:0004679,"Parkinson Disease, Secondary",MESH:D010302,6,Doxorubicin|geraniol|Nicotine|Oxidopamine|Resveratrol|Rotenone,0,
AMP-activated protein kinase activity,GO:0004679,Parkinsonian Disorders,MESH:D020734,7,Carbon Disulfide|geraniol|Lipopolysaccharides|Oxidopamine|Permethrin|Resveratrol|Rotenone,2,LRRK2|PINK1
AMP-activated protein kinase activity,GO:0004679,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
AMP binding,GO:0016208,Parkinson Disease,MESH:D010300,0,,1,FBP1
AMP binding,GO:0016208,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
amylase activity,GO:0016160,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
amylase activity,GO:0016160,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Lipopolysaccharides,0,
amyloid-beta binding,GO:0001540,Parkinson Disease,MESH:D010300,0,,1,INSR
amyloid-beta binding,GO:0001540,"Parkinson Disease, Secondary",MESH:D010302,0,,1,BCHE
amyloid-beta binding,GO:0001540,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
"anandamide 11,12 epoxidase activity",GO:0062188,Parkinson Disease,MESH:D010300,0,,1,CYP2D6
"anandamide 14,15 epoxidase activity",GO:0062189,Parkinson Disease,MESH:D010300,0,,1,CYP2D6
"anandamide 8,9 epoxidase activity",GO:0062187,Parkinson Disease,MESH:D010300,0,,1,CYP2D6
androgen binding,GO:0005497,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A1
angiotensin receptor binding,GO:0031701,Parkinson Disease,MESH:D010300,0,,1,DRD1
antioxidant activity,GO:0016209,Parkinson Disease,MESH:D010300,5,Carbon Tetrachloride|Chlorpyrifos|Melatonin|Particulate Matter|Pentoxifylline,2,SOD1|SOD2
antioxidant activity,GO:0016209,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Melatonin,0,
antioxidant activity,GO:0016209,Parkinsonian Disorders,MESH:D020734,5,coenzyme Q10|Curcumin|Malondialdehyde|Melatonin|Particulate Matter,0,
antioxidant activity,GO:0016209,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
AP-1 adaptor complex binding,GO:0035650,Parkinson Disease,MESH:D010300,0,,1,RAB32
AP-2 adaptor complex binding,GO:0035612,Parkinson Disease,MESH:D010300,0,,1,GAK
AP-3 adaptor complex binding,GO:0035651,Parkinson Disease,MESH:D010300,0,,1,RAB32
apolipoprotein binding,GO:0034185,Parkinson Disease,MESH:D010300,0,,1,MAPT
apolipoprotein binding,GO:0034185,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
apolipoprotein binding,GO:0034185,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
arachidonic acid binding,GO:0050544,Parkinson Disease,MESH:D010300,0,,1,SNCA
arachidonic acid binding,GO:0050544,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
arachidonic acid binding,GO:0050544,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
arachidonic acid binding,GO:0050544,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
arachidonic acid binding,GO:0050544,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
arachidonic acid epoxygenase activity,GO:0008392,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
arachidonic acid omega-hydroxylase activity,GO:0052869,Parkinson Disease,MESH:D010300,0,,1,HMOX1
arginase activity,GO:0004053,Parkinson Disease,MESH:D010300,2,Caffeine|Zinc,0,
arginase activity,GO:0004053,"Parkinson Disease, Secondary",MESH:D010302,2,Haloperidol|Valproic Acid,0,
arginase activity,GO:0004053,Parkinsonian Disorders,MESH:D020734,2,Haloperidol|Valproic Acid,0,
arginine binding,GO:0034618,Parkinson Disease,MESH:D010300,0,,1,NOS1
arginine binding,GO:0034618,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
arginine kinase activity,GO:0004054,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
argininosuccinate lyase activity,GO:0004056,Parkinsonian Disorders,MESH:D020734,1,Zidovudine,0,
aromatase activity,GO:0070330,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
aromatase activity,GO:0070330,"Parkinson Disease, Secondary",MESH:D010302,1,Amlodipine,0,
aromatase activity,GO:0070330,Parkinsonian Disorders,MESH:D020734,1,Amlodipine,0,
aromatic-L-amino-acid decarboxylase activity,GO:0004058,Parkinson Disease,MESH:D010300,0,,1,DDC
aromatic-L-amino-acid decarboxylase activity,GO:0004058,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
arrestin family protein binding,GO:1990763,Parkinson Disease,MESH:D010300,0,,1,DRD1
aryldialkylphosphatase activity,GO:0004063,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,1,PON1
aryldialkylphosphatase activity,GO:0004063,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
arylesterase activity,GO:0004064,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
arylesterase activity,GO:0004064,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PON1
arylesterase activity,GO:0004064,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,0,
aryl hydrocarbon receptor binding,GO:0017162,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process,GO:1902944,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
aspartic-type endopeptidase inhibitor activity,GO:0019828,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
ATP-activated inward rectifier potassium channel activity,GO:0015272,Parkinson Disease,MESH:D010300,1,Zinc,0,
ATPase binding,GO:0051117,Parkinson Disease,MESH:D010300,0,,2,DRD1|NOS1
ATPase binding,GO:0051117,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
ATPase-coupled intramembrane lipid transporter activity,GO:0140326,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
ATPase-coupled intramembrane lipid transporter activity,GO:0140326,Parkinsonian Disorders,MESH:D020734,2,Chlorpromazine|coenzyme Q10,0,
ATPase-coupled monoatomic cation transmembrane transporter activity,GO:0019829,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
ATPase-coupled monoatomic cation transmembrane transporter activity,GO:0019829,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
ATPase-coupled monoatomic cation transmembrane transporter activity,GO:0019829,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
ATPase-coupled transmembrane transporter activity,GO:0042626,Parkinson Disease,MESH:D010300,0,,2,ABCB1|ATP13A2
ATPase-coupled transmembrane transporter activity,GO:0042626,"Parkinson Disease, Secondary",MESH:D010302,0,,2,ABCB1|ATP13A2
ATPase-coupled transmembrane transporter activity,GO:0042626,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
ATP binding,GO:0005524,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
ATP binding,GO:0005524,Parkinson Disease,MESH:D010300,0,,15,ABCB1|ATP13A2|ATPSYNBETA|DDC|GAK|HSC70-3|HSPA1A|HSPA9|IGF1R|INSR|LRRK2|MAP3K5|NECTIN2|PINK1|RAB32
ATP binding,GO:0005524,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
ATP binding,GO:0005524,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
ATP binding,GO:0005524,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
ATP binding,GO:0005524,"Parkinson Disease, Secondary",MESH:D010302,0,,2,ABCB1|ATP13A2
ATP binding,GO:0005524,Parkinsonian Disorders,MESH:D020734,0,,8,ATP13A2|ATP1A3|DCTN1|DDC|LRRK2|PARP1|PINK1|PRKCD
ATP binding,GO:0005524,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
ATP-dependent activity,GO:0140657,Parkinson Disease,MESH:D010300,3,Caffeine|Iron|Lead,0,
ATP-dependent activity,GO:0140657,"Parkinson Disease, Secondary",MESH:D010302,2,Haloperidol|Verapamil,0,
ATP-dependent activity,GO:0140657,Parkinsonian Disorders,MESH:D020734,4,cypermethrin|Haloperidol|manganese chloride|Verapamil,0,
ATP-dependent peptidase activity,GO:0004176,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
ATP-dependent protein binding,GO:0043008,Parkinson Disease,MESH:D010300,0,,1,PINK1
ATP-dependent protein binding,GO:0043008,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
ATP-dependent protein binding,GO:0043008,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
ATP-dependent protein binding,GO:0043008,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
ATP-dependent protein disaggregase activity,GO:0140545,Parkinson Disease,MESH:D010300,0,,1,HSPA1A
ATP-dependent protein folding chaperone,GO:0140662,Parkinson Disease,MESH:D010300,0,,3,HSC70-3|HSPA1A|HSPA9
ATP hydrolysis activity,GO:0016887,Parkinson Disease,MESH:D010300,7,Chlorpyrifos|Lipopolysaccharides|Particulate Matter|Rotenone|Sirolimus|Soot|Vehicle Emissions,8,ABCB1|ATP13A2|ATPSYNBETA|DDC|HSC70-3|HSPA1A|HSPA9|RAB32
ATP hydrolysis activity,GO:0016887,"Parkinson Disease, Secondary",MESH:D010302,5,Cimetidine|Doxorubicin|Resveratrol|Rotenone|Verapamil,2,ABCB1|ATP13A2
ATP hydrolysis activity,GO:0016887,Parkinsonian Disorders,MESH:D020734,9,Cadmium|cypermethrin|Lipopolysaccharides|Particulate Matter|Phenol|Plant Extracts|Resveratrol|Rotenone|Verapamil,5,ATP13A2|ATP1A3|DCTN1|DDC|PARP1
A-type (transient outward) potassium channel activity,GO:0005250,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
A-type (transient outward) potassium channel activity,GO:0005250,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
benzaldehyde dehydrogenase (NAD+) activity,GO:0018479,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A1
beta-2-microglobulin binding,GO:0030881,Parkinson Disease,MESH:D010300,0,,1,HFE
beta-catenin binding,GO:0008013,Parkinson Disease,MESH:D010300,0,,1,PRKN
beta-catenin binding,GO:0008013,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
beta-catenin binding,GO:0008013,"Parkinson Disease, Secondary",MESH:D010302,0,,2,NOS2|PRKN
beta-catenin binding,GO:0008013,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
beta-catenin destruction complex binding,GO:1904713,Parkinson Disease,MESH:D010300,0,,1,LRRK2
beta-catenin destruction complex binding,GO:1904713,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
beta-catenin destruction complex binding,GO:1904713,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
beta-galactosidase activity,GO:0004565,Parkinson Disease,MESH:D010300,5,Air Pollutants|Estradiol|Paraquat|Particulate Matter|Vehicle Emissions,0,
beta-galactosidase activity,GO:0004565,"Parkinson Disease, Secondary",MESH:D010302,2,Paraquat|Resveratrol,0,
beta-galactosidase activity,GO:0004565,Parkinsonian Disorders,MESH:D020734,3,Paraquat|Particulate Matter|Resveratrol,0,
beta-glucosidase activity,GO:0008422,Parkinson Disease,MESH:D010300,0,,1,GBA1
beta-glucosidase activity,GO:0008422,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
beta-glucosidase activity,GO:0008422,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
beta-glucosidase activity,GO:0008422,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
beta-glucuronidase activity,GO:0004566,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
beta-tubulin binding,GO:0048487,Parkinson Disease,MESH:D010300,0,,1,SNCA
beta-tubulin binding,GO:0048487,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
beta-tubulin binding,GO:0048487,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
beta-tubulin binding,GO:0048487,"Parkinson Disease, Secondary",MESH:D010302,1,Vincristine,2,RGS2|SNCA
beta-tubulin binding,GO:0048487,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
BH2 domain binding,GO:0051433,Parkinson Disease,MESH:D010300,0,,1,DNM1L
bHLH transcription factor binding,GO:0043425,Parkinson Disease,MESH:D010300,0,,1,NCAPG2
BLOC-2 complex binding,GO:0036461,Parkinson Disease,MESH:D010300,0,,1,RAB32
boss receptor activity,GO:0008288,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
brain-derived neurotrophic factor receptor activity,GO:0060175,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
C3HC4-type RING finger domain binding,GO:0055131,Parkinson Disease,MESH:D010300,0,,2,HSPA1A|PINK1
C3HC4-type RING finger domain binding,GO:0055131,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
C3HC4-type RING finger domain binding,GO:0055131,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
cadherin binding,GO:0045296,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cadmium ion binding,GO:0046870,Parkinson Disease,MESH:D010300,0,,1,NOS1
cadmium ion transmembrane transporter activity,GO:0015086,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
cADPR-sensitive calcium-release channel activity,GO:0072346,Parkinson Disease,MESH:D010300,1,Lead,0,
calcium-activated potassium channel activity,GO:0015269,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
calcium-activated potassium channel activity,GO:0015269,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
calcium channel activity,GO:0005262,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
calcium channel activity,GO:0005262,Parkinson Disease,MESH:D010300,1,Zinc,1,TRPM2
calcium channel regulator activity,GO:0005246,Parkinson Disease,MESH:D010300,0,,1,NOS1
calcium-dependent ATPase activity,GO:0030899,Parkinson Disease,MESH:D010300,2,Aspirin|Chlorpyrifos,0,
calcium-dependent ATPase activity,GO:0030899,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
calcium-dependent ATPase activity,GO:0030899,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Chlorpromazine|coenzyme Q10,0,
calcium-dependent ATPase activity,GO:0030899,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
calcium-dependent protein binding,GO:0048306,Parkinson Disease,MESH:D010300,0,,1,NOS1
calcium-dependent protein kinase C activity,GO:0004698,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
calcium-independent phospholipase A2 activity,GO:0047499,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
calcium-independent protein kinase C activity,GO:0004699,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
calcium ion binding,GO:0005509,Parkinson Disease,MESH:D010300,0,,7,AIF1|CNTNAP2|CNX99A|NOS1|SNCA|TRPM2|UP
calcium ion binding,GO:0005509,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
calcium ion binding,GO:0005509,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
calcium ion binding,GO:0005509,"Parkinson Disease, Secondary",MESH:D010302,0,,4,BCHE|PON1|SHH|SNCA
calcium ion binding,GO:0005509,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
calcium-release channel activity,GO:0015278,Parkinson Disease,MESH:D010300,0,,1,TRPM2
calmodulin binding,GO:0005516,Parkinson Disease,MESH:D010300,0,,2,MAP2|NOS1
calmodulin binding,GO:0005516,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
calmodulin binding,GO:0005516,"Parkinson Disease, Secondary",MESH:D010302,0,,2,NOS2|RGS2
calmodulin-dependent protein kinase activity,GO:0004683,"Parkinson Disease, Secondary",MESH:D010302,1,Vincristine,0,
calmodulin-dependent protein phosphatase activity,GO:0033192,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,0,
calmodulin-dependent protein phosphatase activity,GO:0033192,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
cAMP-dependent protein kinase activity,GO:0004691,Parkinson Disease,MESH:D010300,1,Roflumilast,0,
cAMP-dependent protein kinase inhibitor activity,GO:0004862,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
cAMP-dependent protein kinase regulator activity,GO:0008603,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cAMP-dependent protein kinase regulator activity,GO:0008603,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
cannabinoid receptor activity,GO:0004949,"Parkinson Disease, Secondary",MESH:D010302,0,,1,CNR2
carbohydrate binding,GO:0030246,Parkinson Disease,MESH:D010300,0,,2,MAG|TALDO1
carbonate dehydratase activity,GO:0004089,Parkinson Disease,MESH:D010300,2,Caffeine|Copper,0,
carbonate dehydratase activity,GO:0004089,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
carbonate dehydratase activity,GO:0004089,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
carbon-carbon lyase activity,GO:0016830,Parkinson Disease,MESH:D010300,0,,1,DDC
carbon-carbon lyase activity,GO:0016830,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
carboxylesterase activity,GO:0106435,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,1,ALDH2
carboxylic acid transmembrane transporter activity,GO:0046943,Parkinson Disease,MESH:D010300,0,,1,ABCB1
carboxylic acid transmembrane transporter activity,GO:0046943,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
carboxylic ester hydrolase activity,GO:0052689,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Permethrin,0,
carboxylic ester hydrolase activity,GO:0052689,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,1,BCHE
carboxylic ester hydrolase activity,GO:0052689,Parkinsonian Disorders,MESH:D020734,2,geraniol|Permethrin,0,
carboxy-lyase activity,GO:0016831,Parkinson Disease,MESH:D010300,0,,1,DDC
carboxy-lyase activity,GO:0016831,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
cardiolipin binding,GO:1901612,Parkinson Disease,MESH:D010300,1,Lead,0,
cargo receptor activity,GO:0038024,Parkinson Disease,MESH:D010300,0,,2,INSR|VPS35
cargo receptor activity,GO:0038024,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
carnitine O-palmitoyltransferase activity,GO:0004095,Parkinson Disease,MESH:D010300,1,Copper,0,
carnitine O-palmitoyltransferase activity,GO:0004095,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
carnitine O-palmitoyltransferase activity,GO:0004095,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
catalase activity,GO:0004096,Parkinson Disease,MESH:D010300,2,Eugenol|Pesticides,0,
catalase activity,GO:0004096,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
catalase activity,GO:0004096,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,0,
catalase activity,GO:0004096,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
catalytic activity,GO:0003824,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
catalytic activity,GO:0003824,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
catalytic activity,GO:0003824,"Parkinson Disease, Secondary",MESH:D010302,0,,1,BCHE
catalytic activity,GO:0003824,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
CD40 receptor binding,GO:0005174,Parkinson Disease,MESH:D010300,0,,1,TNF
cell adhesion molecule binding,GO:0050839,Parkinson Disease,MESH:D010300,0,,3,FGB|MAG|NECTIN2
ceramide floppase activity,GO:0099038,Parkinson Disease,MESH:D010300,0,,1,ABCB1
ceramide floppase activity,GO:0099038,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
channel activity,GO:0015267,Parkinson Disease,MESH:D010300,2,Copper|Zinc,0,
channel activity,GO:0015267,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
chaperone binding,GO:0051087,Parkinson Disease,MESH:D010300,0,,8,BAG5|CP|FGB|GAK|HSPA9|MAPT|PRKN|SOD1
chaperone binding,GO:0051087,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
chaperone binding,GO:0051087,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
chaperone binding,GO:0051087,Parkinsonian Disorders,MESH:D020734,0,,3,ATP1A3|MAPT|PRKN
chemoattractant activity,GO:0042056,Parkinson Disease,MESH:D010300,0,,1,HGF
chemoattractant activity involved in axon guidance,GO:1902379,Parkinson Disease,MESH:D010300,0,,1,GDNF
chemoattractant activity involved in axon guidance,GO:1902379,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
chemoattractant activity involved in axon guidance,GO:1902379,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
chloride transmembrane transporter activity,GO:0015108,Parkinson Disease,MESH:D010300,1,Estradiol,0,
cholesterol-protein transferase activity,GO:0140853,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
choline binding,GO:0033265,"Parkinson Disease, Secondary",MESH:D010302,0,,1,BCHE
cholinesterase activity,GO:0004104,Parkinson Disease,MESH:D010300,8,Chlorpyrifos|Diazinon|Insecticides|Manganese|Methomyl|Organophosphates|Pesticides|profenamine,0,
cholinesterase activity,GO:0004104,"Parkinson Disease, Secondary",MESH:D010302,3,Manganese|Pesticides|Tacrine,1,BCHE
cholinesterase activity,GO:0004104,Parkinsonian Disorders,MESH:D020734,2,Manganese|profenamine,0,
chromatin binding,GO:0003682,Parkinson Disease,MESH:D010300,0,,3,MAP2|MTA1|PPARGC1A
chromatin binding,GO:0003682,"Parkinson Disease, Secondary",MESH:D010302,0,,1,TFAM
chromatin binding,GO:0003682,Parkinsonian Disorders,MESH:D020734,0,,2,PARP1|POLG
chromatin DNA binding,GO:0031490,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
clathrin binding,GO:0030276,Parkinson Disease,MESH:D010300,0,,3,DNM1L|GAK|LRRK2
clathrin binding,GO:0030276,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
clathrin binding,GO:0030276,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
clathrin binding,GO:0030276,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
clathrin heavy chain binding,GO:0032050,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
collagen binding involved in cell-matrix adhesion,GO:0098639,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
collagen binding involved in cell-matrix adhesion,GO:0098639,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
copper ion binding,GO:0005507,Parkinson Disease,MESH:D010300,0,,4,CP|PARK7|SNCA|SOD1
copper ion binding,GO:0005507,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
copper ion binding,GO:0005507,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
copper ion binding,GO:0005507,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
copper ion binding,GO:0005507,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
copper ion binding,GO:0005507,Parkinsonian Disorders,MESH:D020734,0,,2,PARK7|SNCA
coreceptor activity,GO:0015026,Parkinson Disease,MESH:D010300,0,,1,NECTIN2
co-receptor binding,GO:0039706,Parkinson Disease,MESH:D010300,0,,2,HFE|LRRK2
co-receptor binding,GO:0039706,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
co-receptor binding,GO:0039706,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
core promoter sequence-specific DNA binding,GO:0001046,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
coumarin 7-hydroxylase activity,GO:0008389,Parkinson Disease,MESH:D010300,1,Permethrin,0,
coumarin 7-hydroxylase activity,GO:0008389,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
creatine kinase activity,GO:0004111,Parkinson Disease,MESH:D010300,2,Lead|Lipopolysaccharides,0,
creatine kinase activity,GO:0004111,"Parkinson Disease, Secondary",MESH:D010302,3,Doxorubicin|geraniol|Resveratrol,0,
creatine kinase activity,GO:0004111,Parkinsonian Disorders,MESH:D020734,7,baicalin|Cadmium|coenzyme Q10|crocin|geraniol|Lipopolysaccharides|Resveratrol,0,
creatine kinase activity,GO:0004111,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cullin family protein binding,GO:0097602,Parkinson Disease,MESH:D010300,0,,1,PRKN
cullin family protein binding,GO:0097602,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
cullin family protein binding,GO:0097602,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
cupric ion binding,GO:1903135,Parkinson Disease,MESH:D010300,0,,2,ATP13A2|PARK7
cupric ion binding,GO:1903135,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cupric ion binding,GO:1903135,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
cupric ion binding,GO:1903135,Parkinsonian Disorders,MESH:D020734,0,,2,ATP13A2|PARK7
cuprous ion binding,GO:1903136,Parkinson Disease,MESH:D010300,0,,2,PARK7|SNCA
cuprous ion binding,GO:1903136,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
cuprous ion binding,GO:1903136,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
cuprous ion binding,GO:1903136,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cuprous ion binding,GO:1903136,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
cuprous ion binding,GO:1903136,Parkinsonian Disorders,MESH:D020734,0,,2,PARK7|SNCA
cyclin binding,GO:0030332,Parkinson Disease,MESH:D010300,0,,1,GAK
cysteine-S-conjugate beta-lyase activity,GO:0047804,Parkinson Disease,MESH:D010300,1,Trichloroethylene,0,
cysteine-S-conjugate beta-lyase activity,GO:0047804,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
cysteine-type deubiquitinase activity,GO:0004843,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
cysteine-type deubiquitinase activity,GO:0004843,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
cysteine-type deubiquitinase activity,GO:0004843,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0008656,Parkinson Disease,MESH:D010300,0,,1,NGF
cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0008656,Parkinsonian Disorders,MESH:D020734,0,,1,NGF
cysteine-type endopeptidase activity,GO:0004197,Parkinson Disease,MESH:D010300,8,1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Dopamine|Lipopolysaccharides|Paclitaxel|Particulate Matter|Vehicle Emissions,0,
cysteine-type endopeptidase activity,GO:0004197,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
cysteine-type endopeptidase activity,GO:0004197,"Parkinson Disease, Secondary",MESH:D010302,4,3-methyladenine|Amiodarone|Doxorubicin|perhexiline maleate,0,
cysteine-type endopeptidase activity,GO:0004197,Parkinsonian Disorders,MESH:D020734,9,1-Methyl-4-phenylpyridinium|Amiodarone|Cadmium|cypermethrin|Dopamine|genkwanin|linsidomine|Lipopolysaccharides|Particulate Matter,1,PRKRA
cysteine-type endopeptidase activity,GO:0004197,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
cysteine-type endopeptidase activity involved in apoptotic process,GO:0097153,Parkinson Disease,MESH:D010300,3,Chlorpyrifos|Homocysteine|Ketoconazole,0,
cysteine-type endopeptidase activity involved in apoptotic process,GO:0097153,Parkinsonian Disorders,MESH:D020734,1,Ketoconazole,0,
cysteine-type endopeptidase inhibitor activity,GO:0004869,Parkinson Disease,MESH:D010300,0,,1,SNCA
cysteine-type endopeptidase inhibitor activity,GO:0004869,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
cysteine-type endopeptidase inhibitor activity,GO:0004869,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
cysteine-type endopeptidase inhibitor activity,GO:0004869,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
cysteine-type endopeptidase inhibitor activity,GO:0004869,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0043027,Parkinson Disease,MESH:D010300,0,,1,SNCA
cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0043027,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0043027,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0043027,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0043027,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
cysteine-type peptidase activity,GO:0008234,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
cysteine-type peptidase activity,GO:0008234,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
cysteine-type peptidase activity,GO:0008234,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
cysteine-type peptidase activity,GO:0008234,Parkinsonian Disorders,MESH:D020734,1,crocin,0,
"cytochrome-b5 reductase activity, acting on NADH",GO:0090524,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
"cytochrome-b5 reductase activity, acting on NAD(P)H",GO:0004128,Parkinson Disease,MESH:D010300,0,,1,NQO1
cytochrome-c oxidase activity,GO:0004129,Parkinson Disease,MESH:D010300,21,1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Air Pollutants|Aspirin|Copper|Dicamba|Iron|Lead|Lipopolysaccharides|mangiferin|Nitrites|Ozone|Paraquat|Particulate Matter|Pesticides|Rotenone|Sirolimus|Soot|Vehicle Emissions|Zinc,0,
cytochrome-c oxidase activity,GO:0004129,"Parkinson Disease, Secondary",MESH:D010302,8,Benzo(a)pyrene|Doxorubicin|Exenatide|Paraquat|Pesticides|Resveratrol|Rotenone|sodium bisulfide,0,
cytochrome-c oxidase activity,GO:0004129,Parkinsonian Disorders,MESH:D020734,10,1-Methyl-4-phenylpyridinium|Cadmium|coenzyme Q10|Curcumin|Lipopolysaccharides|oleuropein|Paraquat|Particulate Matter|Resveratrol|Rotenone,0,
cytochrome-c oxidase activity,GO:0004129,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cytokine activity,GO:0005125,Parkinson Disease,MESH:D010300,0,,3,EDN1|IL6|TNF
cytokine binding,GO:0019955,Parkinson Disease,MESH:D010300,0,,1,PARK7
cytokine binding,GO:0019955,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cytokine binding,GO:0019955,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
cytoskeletal regulatory protein binding,GO:0005519,Parkinson Disease,MESH:D010300,0,,1,MAP2
D1 dopamine receptor binding,GO:0031748,Parkinson Disease,MESH:D010300,0,,1,VPS35
D1 dopamine receptor binding,GO:0031748,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
D1 dopamine receptor binding,GO:0031748,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
D3 dopamine receptor binding,GO:0031750,Parkinson Disease,MESH:D010300,0,,1,DRD1
D-alanine:2-oxoglutarate aminotransferase activity,GO:0047810,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
D-alanine:2-oxoglutarate aminotransferase activity,GO:0047810,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
damaged DNA binding,GO:0003684,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
death receptor agonist activity,GO:0038177,Parkinson Disease,MESH:D010300,0,,3,HSPA1A|NGF|TNF
death receptor agonist activity,GO:0038177,Parkinsonian Disorders,MESH:D020734,0,,1,NGF
dehydroascorbic acid transmembrane transporter activity,GO:0033300,Parkinson Disease,MESH:D010300,0,,1,SLC2A14
denatured protein binding,GO:0031249,Parkinson Disease,MESH:D010300,0,,1,HSPA1A
D-glucose transmembrane transporter activity,GO:0055056,Parkinson Disease,MESH:D010300,0,,1,SLC2A14
D-glutamyltransferase activity,GO:0047823,Parkinson Disease,MESH:D010300,4,Air Pollutants|Carbon Tetrachloride|Particulate Matter|Zinc,0,
D-glutamyltransferase activity,GO:0047823,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Doxorubicin|geraniol,0,
D-glutamyltransferase activity,GO:0047823,Parkinsonian Disorders,MESH:D020734,3,geraniol|Particulate Matter|taxifolin,0,
diacylglycerol kinase activity,GO:0004143,Parkinson Disease,MESH:D010300,0,,1,RDGA
dimethylargininase activity,GO:0016403,Parkinson Disease,MESH:D010300,1,Homocysteine,0,
dinitrosyl-iron complex binding,GO:0035731,Parkinson Disease,MESH:D010300,0,,1,GSTP1
disordered domain specific binding,GO:0097718,Parkinson Disease,MESH:D010300,0,,1,HSPA1A
disordered domain specific binding,GO:0097718,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
DNA binding,GO:0003677,Parkinson Disease,MESH:D010300,0,,6,MAPT|NOS1|PPARGC1A|RPL23A|RPL6|SOD2
DNA binding,GO:0003677,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,3,MAPT|NR4A2|TBP
DNA binding,GO:0003677,"Parkinson Disease, Secondary",MESH:D010302,0,,1,TFAM
DNA binding,GO:0003677,Parkinsonian Disorders,MESH:D020734,0,,3,MAPT|PARP1|POLG
"DNA binding, bending",GO:0008301,"Parkinson Disease, Secondary",MESH:D010302,0,,1,TFAM
DNA-binding transcription activator activity,GO:0001216,Parkinson Disease,MESH:D010300,1,Rotenone,0,
DNA-binding transcription activator activity,GO:0001216,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
DNA-binding transcription activator activity,GO:0001216,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
"DNA-binding transcription activator activity, RNA polymerase II-specific",GO:0001228,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
DNA-binding transcription factor activity,GO:0003700,Parkinson Disease,MESH:D010300,3,Estradiol|Lipopolysaccharides|Ozone,0,
DNA-binding transcription factor activity,GO:0003700,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Lipopolysaccharides,0,
"DNA-binding transcription factor activity, RNA polymerase II-specific",GO:0000981,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
DNA-binding transcription factor binding,GO:0140297,Parkinson Disease,MESH:D010300,0,,2,PARK7|PPARGC1A
DNA-binding transcription factor binding,GO:0140297,"PARKINSON DISEASE 22, AUTOSOMAL DOMINANT",OMIM:616710,0,,1,CHCHD2
DNA-binding transcription factor binding,GO:0140297,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
DNA-binding transcription factor binding,GO:0140297,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
DNA-binding transcription factor binding,GO:0140297,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
DNA-dependent protein kinase activity,GO:0004677,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
DNA-dependent protein kinase activity,GO:0004677,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
DNA-dependent protein kinase activity,GO:0004677,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
DNA-dependent protein kinase activity,GO:0004677,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
DNA-dependent protein kinase activity,GO:0004677,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
DNA-directed DNA polymerase activity,GO:0003887,Parkinsonian Disorders,MESH:D020734,0,,1,POLG
DNA-methyltransferase activity,GO:0009008,Parkinson Disease,MESH:D010300,1,Estradiol,0,
DNA-methyltransferase activity,GO:0009008,"Parkinson Disease, Secondary",MESH:D010302,1,Exenatide,0,
DNA-methyltransferase activity,GO:0009008,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Plant Extracts,0,
dopamine binding,GO:0035240,Parkinson Disease,MESH:D010300,0,,4,DRD1|DRD2|SLC6A3|TH
dopamine binding,GO:0035240,Parkinsonian Disorders,MESH:D020734,0,,2,DRD2|TH
dopamine binding,GO:0035240,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
dopamine neurotransmitter receptor activity,GO:0004952,Parkinson Disease,MESH:D010300,0,,2,DRD1|DRD2
dopamine neurotransmitter receptor activity,GO:0004952,Parkinsonian Disorders,MESH:D020734,0,,2,DOP1R2|DRD2
"dopamine neurotransmitter receptor activity, coupled via Gi/Go",GO:0001591,Parkinson Disease,MESH:D010300,0,,1,DRD2
"dopamine neurotransmitter receptor activity, coupled via Gi/Go",GO:0001591,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
"dopamine neurotransmitter receptor activity, coupled via Gs",GO:0001588,Parkinson Disease,MESH:D010300,0,,1,DRD1
"dopamine neurotransmitter receptor activity, coupled via Gs",GO:0001588,Parkinsonian Disorders,MESH:D020734,0,,1,DOP1R2
dopamine:sodium symporter activity,GO:0005330,Parkinson Disease,MESH:D010300,0,,1,SLC6A3
dopamine:sodium symporter activity,GO:0005330,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
double-stranded DNA binding,GO:0003690,Parkinson Disease,MESH:D010300,0,,1,MAPT
double-stranded DNA binding,GO:0003690,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
double-stranded DNA binding,GO:0003690,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
double-stranded RNA adenosine deaminase activity,GO:0003726,Parkinson Disease,MESH:D010300,0,,1,ADARB2
double-stranded RNA binding,GO:0003725,Parkinson Disease,MESH:D010300,0,,2,ADARB2|HSPA1A
double-stranded RNA binding,GO:0003725,Parkinsonian Disorders,MESH:D020734,0,,1,PRKRA
D-sorbitol dehydrogenase (acceptor) activity,GO:0047833,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
D-sorbitol dehydrogenase (acceptor) activity,GO:0047833,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
dynactin binding,GO:0034452,Parkinson Disease,MESH:D010300,0,,1,MAPT
dynactin binding,GO:0034452,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
dynactin binding,GO:0034452,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
dynein complex binding,GO:0070840,Parkinson Disease,MESH:D010300,0,,1,SNCA
dynein complex binding,GO:0070840,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
dynein complex binding,GO:0070840,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
dynein complex binding,GO:0070840,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
dynein complex binding,GO:0070840,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
dystroglycan binding,GO:0002162,Parkinson Disease,MESH:D010300,0,,1,MAP2
efflux transmembrane transporter activity,GO:0015562,Parkinson Disease,MESH:D010300,0,,1,ABCB1
efflux transmembrane transporter activity,GO:0015562,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
EH domain binding,GO:1990175,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
electron transfer activity,GO:0009055,Parkinson Disease,MESH:D010300,0,,2,ALDH2|MAOB
electron transfer activity,GO:0009055,Parkinsonian Disorders,MESH:D020734,0,,1,GSR
endopeptidase activity,GO:0004175,Parkinson Disease,MESH:D010300,2,4-phenylbutyric acid|Particulate Matter,1,HGF
endopeptidase activity,GO:0004175,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
endopeptidase activity,GO:0004175,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
endoplasmic reticulum-autophagosome adaptor activity,GO:0140506,Parkinson Disease,MESH:D010300,0,,1,RTNL1
endothelin A receptor binding,GO:0031707,Parkinson Disease,MESH:D010300,0,,1,EDN1
endothelin B receptor binding,GO:0031708,Parkinson Disease,MESH:D010300,0,,1,EDN1
enzyme activator activity,GO:0008047,Parkinson Disease,MESH:D010300,0,,1,PARK7
enzyme activator activity,GO:0008047,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
enzyme activator activity,GO:0008047,Parkinsonian Disorders,MESH:D020734,0,,4,PARK7|PARP1|PRKCD|PRKRA
enzyme binding,GO:0019899,Parkinson Disease,MESH:D010300,0,,19,CNTNAP2|CYP2E1|DDC|ENO2|GSTM1|HMOX1|HSPA1A|HSPA9|IGF2R|MAPT|MTA1|NOS1|PARK7|PRKN|SLC18A2|SNCA|SOD1|SOD2|TH
enzyme binding,GO:0019899,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
enzyme binding,GO:0019899,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
enzyme binding,GO:0019899,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
enzyme binding,GO:0019899,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,MAPT|TBP
enzyme binding,GO:0019899,"Parkinson Disease, Secondary",MESH:D010302,0,,4,BCHE|PRKN|SLC18A2|SNCA
enzyme binding,GO:0019899,Parkinsonian Disorders,MESH:D020734,0,,11,DDC|GAPDH|MAPT|PARK7|PARP1|PRKCD|PRKN|PRKRA|SLC18A2|SNCA|TH
enzyme inhibitor activity,GO:0004857,Parkinson Disease,MESH:D010300,0,,1,SNCA
enzyme inhibitor activity,GO:0004857,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
enzyme inhibitor activity,GO:0004857,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
enzyme inhibitor activity,GO:0004857,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
enzyme inhibitor activity,GO:0004857,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
epidermal growth factor receptor activity,GO:0005006,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
epidermal growth factor receptor binding,GO:0005154,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN2
estradiol 17-beta-dehydrogenase activity,GO:0004303,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
estradiol 17-beta-dehydrogenase activity,GO:0004303,Parkinsonian Disorders,MESH:D020734,5,Chlorpromazine|coenzyme Q10|Curcumin|cypermethrin|Indomethacin,0,
eukaryotic initiation factor 4E binding,GO:0008190,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
eukaryotic translation initiation factor 2alpha kinase activity,GO:0004694,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
eukaryotic translation initiation factor 2alpha kinase activity,GO:0004694,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
eukaryotic translation initiation factor 2alpha kinase activity,GO:0004694,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
eukaryotic translation initiation factor 2alpha kinase activity,GO:0004694,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
eukaryotic translation initiation factor 2alpha kinase activity,GO:0004694,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
exonuclease activity,GO:0004527,Parkinsonian Disorders,MESH:D020734,0,,1,POLG
extracellular matrix structural constituent,GO:0005201,Parkinson Disease,MESH:D010300,0,,2,COL19A1|FGB
extracellular matrix structural constituent conferring tensile strength,GO:0030020,Parkinson Disease,MESH:D010300,0,,1,COL19A1
FAD binding,GO:0071949,Parkinson Disease,MESH:D010300,0,,1,MTHFR
fatty acid binding,GO:0005504,Parkinson Disease,MESH:D010300,0,,1,GSTP1
F-box domain binding,GO:1990444,Parkinson Disease,MESH:D010300,0,,1,PRKN
F-box domain binding,GO:1990444,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
F-box domain binding,GO:1990444,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
ferric iron binding,GO:0008199,Parkinson Disease,MESH:D010300,0,,1,TH
ferric iron binding,GO:0008199,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
ferric iron binding,GO:0008199,Parkinsonian Disorders,MESH:D020734,0,,1,TH
ferrous iron binding,GO:0008198,Parkinson Disease,MESH:D010300,0,,2,SNCA|TH
ferrous iron binding,GO:0008198,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
ferrous iron binding,GO:0008198,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
ferrous iron binding,GO:0008198,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
ferrous iron binding,GO:0008198,Parkinsonian Disorders,MESH:D020734,0,,2,SNCA|TH
ferrous iron transmembrane transporter activity,GO:0015093,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
ferroxidase activity,GO:0004322,Parkinson Disease,MESH:D010300,0,,1,CP
fibroblast growth factor binding,GO:0017134,Parkinson Disease,MESH:D010300,0,,1,HSPA9
fibroblast growth factor receptor activity,GO:0005007,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
flavin adenine dinucleotide binding,GO:0050660,Parkinson Disease,MESH:D010300,0,,6,ALDH2|CPR|MAOA|MAOB|MTHFR|NOS1
flavin adenine dinucleotide binding,GO:0050660,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
flavin adenine dinucleotide binding,GO:0050660,Parkinsonian Disorders,MESH:D020734,0,,1,GSR
floppase activity,GO:0140328,Parkinson Disease,MESH:D010300,0,,1,ABCB1
floppase activity,GO:0140328,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
FMN binding,GO:0010181,Parkinson Disease,MESH:D010300,0,,2,CPR|NOS1
FMN binding,GO:0010181,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
frizzled binding,GO:0005109,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
"fructose 1,6-bisphosphate 1-phosphatase activity",GO:0042132,Parkinson Disease,MESH:D010300,0,,1,FBP1
"fructose 1,6-bisphosphate 1-phosphatase activity",GO:0042132,"Parkinson Disease, Secondary",MESH:D010302,1,thymoquinone,0,
galactosylceramidase activity,GO:0004336,Parkinson Disease,MESH:D010300,0,,1,GBA1
galactosylceramidase activity,GO:0004336,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
galactosylceramidase activity,GO:0004336,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
ganglioside GT1b binding,GO:1905576,Parkinson Disease,MESH:D010300,0,,1,MAG
gap junction channel activity,GO:0005243,Parkinson Disease,MESH:D010300,4,Air Pollutants|Hexachlorocyclohexane|Lead|Particulate Matter,0,
gap junction channel activity,GO:0005243,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Resveratrol,0,
gap junction channel activity,GO:0005243,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Resveratrol,0,
general transcription initiation factor binding,GO:0140296,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
Gi/o-coupled serotonin receptor activity,GO:0001586,Parkinson Disease,MESH:D010300,1,Sirolimus,0,
glial cell-derived neurotrophic factor receptor binding,GO:0030116,Parkinson Disease,MESH:D010300,0,,1,GDNF
glial cell-derived neurotrophic factor receptor binding,GO:0030116,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
glial cell-derived neurotrophic factor receptor binding,GO:0030116,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
glucokinase activity,GO:0004340,Parkinson Disease,MESH:D010300,1,Lithium Carbonate,0,
glucokinase activity,GO:0004340,"Parkinson Disease, Secondary",MESH:D010302,1,Lithium Carbonate,0,
glucokinase activity,GO:0004340,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
glucose-6-phosphatase activity,GO:0004346,"Parkinson Disease, Secondary",MESH:D010302,2,geraniol|thymoquinone,0,
glucose-6-phosphatase activity,GO:0004346,Parkinsonian Disorders,MESH:D020734,2,geraniol|Plant Extracts,0,
glucose-6-phosphate dehydrogenase activity,GO:0004345,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
glucosylceramidase activity,GO:0004348,Parkinson Disease,MESH:D010300,0,,1,GBA1
glucosylceramidase activity,GO:0004348,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
glucosylceramidase activity,GO:0004348,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
glucosyltransferase activity,GO:0046527,Parkinson Disease,MESH:D010300,0,,1,GBA1
glucosyltransferase activity,GO:0046527,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
glucosyltransferase activity,GO:0046527,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
glucuronosyltransferase activity,GO:0015020,Parkinson Disease,MESH:D010300,3,Carbon Tetrachloride|Estradiol|Tea,0,
glucuronosyltransferase activity,GO:0015020,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
glucuronosyltransferase activity,GO:0015020,Parkinsonian Disorders,MESH:D020734,1,Plant Preparations,0,
glutamate-cysteine ligase activity,GO:0004357,Parkinson Disease,MESH:D010300,1,Lead,0,
glutamate-cysteine ligase activity,GO:0004357,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
glutamate dehydrogenase (NAD+) activity,GO:0004352,Parkinson Disease,MESH:D010300,2,Carbon Tetrachloride|Melatonin,0,
glutamate dehydrogenase (NAD+) activity,GO:0004352,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
glutamate dehydrogenase (NAD+) activity,GO:0004352,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
glutathione binding,GO:0043295,Parkinson Disease,MESH:D010300,2,Copper|Manganese,1,GSTM1
glutathione binding,GO:0043295,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
glutathione binding,GO:0043295,Parkinsonian Disorders,MESH:D020734,2,Manganese|manganese chloride,1,GSR
glutathione disulfide oxidoreductase activity,GO:0015038,Parkinson Disease,MESH:D010300,0,,1,RPL23A
glutathione-disulfide reductase (NADPH) activity,GO:0004362,Parkinson Disease,MESH:D010300,1,Pesticides,0,
glutathione-disulfide reductase (NADPH) activity,GO:0004362,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
glutathione-disulfide reductase (NADPH) activity,GO:0004362,Parkinsonian Disorders,MESH:D020734,0,,1,GSR
glutathione peroxidase activity,GO:0004602,Parkinson Disease,MESH:D010300,45,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Air Pollutants|Aluminum|Atrazine|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Clozapine|Coffee|Copper|Diazepam|Diazinon|Ditiocarb|Estradiol|Homocysteine|Iron|Lead|Lipopolysaccharides|Lithium|Lithium Carbonate|Manganese|mangiferin|Melatonin|Methamphetamine|Oxidopamine|Ozone|Paclitaxel|Paraquat|Particulate Matter|Permethrin|Pesticides|Pioglitazone|Probenecid|Rotenone|Sirolimus|Smoke|Soot|Tea|tetrachloroisophthalonitrile|Vehicle Emissions|Water Pollutants, Chemical|Zinc",2,CP|GSTP1
glutathione peroxidase activity,GO:0004602,"Parkinson Disease, Secondary",MESH:D010302,29,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amiodarone|Atrazine|Benzo(a)pyrene|Diazepam|Dichlorvos|Ditiocarb|Doxorubicin|geraniol|Lithium|Lithium Carbonate|Manganese|Melatonin|Methamphetamine|Methotrexate|Nicotine|Oxidopamine|Paraquat|Pesticides|Pyridostigmine Bromide|Resveratrol|Rotenone|Silymarin|sodium bisulfide|Tacrine|thymoquinone|Valproic Acid|Vincristine",0,
glutathione peroxidase activity,GO:0004602,Parkinsonian Disorders,MESH:D020734,33,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Amiodarone|Cadmium|Clozapine|coenzyme Q10|Coffee|crocin|Curcumin|cypermethrin|Diazoxide|Docosahexaenoic Acids|geraniol|ginsenoside Re|Indomethacin|Lipopolysaccharides|Malondialdehyde|mancozeb|Manganese|manganese chloride|Melatonin|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Plant Preparations|Probenecid|Resveratrol|Rotenone|Silymarin|taxifolin|Valproic Acid",0,
glutathione peroxidase activity,GO:0004602,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Amiodarone|Isoproterenol|Lithium,0,
glutathione transferase activity,GO:0004364,Parkinson Disease,MESH:D010300,33,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Atrazine|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Copper|Dopamine|Endosulfan|Ethylene Dibromide|Eugenol|Hydrocarbons, Chlorinated|Iron|Lead|Levodopa|Lipopolysaccharides|Lithium Carbonate|Manganese|mangiferin|Melatonin|Methomyl|Ozone|Paclitaxel|Paraquat|Particulate Matter|Permethrin|Pesticides|Pioglitazone|Rotenone|Trichloroethylene|Vehicle Emissions|Water Pollutants, Chemical|Zinc",3,GSTA4|GSTM1|GSTP1
glutathione transferase activity,GO:0004364,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
glutathione transferase activity,GO:0004364,"Parkinson Disease, Secondary",MESH:D010302,23,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Benzo(a)pyrene|Buspirone|Dichlorvos|Doxorubicin|geraniol|Hydrocarbons, Chlorinated|Levodopa|Lithium Carbonate|Manganese|Melatonin|Methotrexate|Nicotine|Paraquat|Pesticides|Resveratrol|Rotenone|Silymarin|sodium bisulfide|thymoquinone|Trichloroethylene|Valproic Acid",0,
glutathione transferase activity,GO:0004364,Parkinsonian Disorders,MESH:D020734,24,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Buspirone|Cadmium|crocin|Curcumin|cypermethrin|Dopamine|geraniol|Levodopa|Lipopolysaccharides|mancozeb|Manganese|manganese chloride|Melatonin|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Plant Preparations|Resveratrol|Rotenone|Silymarin|Valproic Acid",0,
glutathione transferase activity,GO:0004364,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity,GO:0004365,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
glycerol-3-phosphate dehydrogenase [NAD(P)+] activity,GO:0047952,Parkinson Disease,MESH:D010300,0,,1,GPDH1
glycerol-3-phosphate O-acyltransferase activity,GO:0004366,"PARKINSON DISEASE 22, AUTOSOMAL DOMINANT",OMIM:616710,0,,1,CHCHD2
glycerol-3-phosphate O-acyltransferase activity,GO:0004366,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
glycerol-3-phosphate O-acyltransferase activity,GO:0004366,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
glycogen phosphorylase activity,GO:0008184,Parkinson Disease,MESH:D010300,1,Lithium Carbonate,0,
glycogen phosphorylase activity,GO:0008184,"Parkinson Disease, Secondary",MESH:D010302,1,Lithium Carbonate,0,
glycogen phosphorylase activity,GO:0008184,Parkinsonian Disorders,MESH:D020734,2,cypermethrin|Plant Extracts,0,
glycogen (starch) synthase activity,GO:0004373,Parkinson Disease,MESH:D010300,1,Lithium Carbonate,0,
glycogen (starch) synthase activity,GO:0004373,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
glycogen (starch) synthase activity,GO:0004373,"Parkinson Disease, Secondary",MESH:D010302,1,Lithium Carbonate,0,
glycogen (starch) synthase activity,GO:0004373,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
glycosaminoglycan binding,GO:0005539,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
glycosyltransferase activity,GO:0016757,Parkinson Disease,MESH:D010300,0,,1,CPR
glycosyltransferase activity,GO:0016757,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
glycosyltransferase activity,GO:0016757,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
glyoxalase (glycolic acid-forming) activity,GO:1990422,Parkinson Disease,MESH:D010300,0,,1,PARK7
glyoxalase (glycolic acid-forming) activity,GO:1990422,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
glyoxalase (glycolic acid-forming) activity,GO:1990422,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
GPI-linked ephrin receptor activity,GO:0005004,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
G-protein activated inward rectifier potassium channel activity,GO:0015467,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
G-protein alpha-subunit binding,GO:0001965,Parkinson Disease,MESH:D010300,0,,4,DRD1|DRD2|IGF1R|IGF2R
G-protein alpha-subunit binding,GO:0001965,"Parkinson Disease, Secondary",MESH:D010302,0,,1,RGS2
G-protein alpha-subunit binding,GO:0001965,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
G protein-coupled amine receptor activity,GO:0008227,Parkinsonian Disorders,MESH:D020734,0,,1,DOP1R2
G protein-coupled receptor activity,GO:0004930,Parkinson Disease,MESH:D010300,0,,2,DRD1|DRD2
G protein-coupled receptor activity,GO:0004930,"Parkinson Disease, Secondary",MESH:D010302,0,,1,CNR2
G protein-coupled receptor activity,GO:0004930,Parkinsonian Disorders,MESH:D020734,0,,2,DOP1R2|DRD2
G protein-coupled receptor binding,GO:0001664,Parkinson Disease,MESH:D010300,0,,2,HSPA1A|PRKN
G protein-coupled receptor binding,GO:0001664,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
G protein-coupled receptor binding,GO:0001664,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
growth factor activity,GO:0008083,Parkinson Disease,MESH:D010300,0,,6,BDNF|GDNF|HGF|IGF2|IL6|NGF
growth factor activity,GO:0008083,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
growth factor activity,GO:0008083,Parkinsonian Disorders,MESH:D020734,0,,2,GDNF|NGF
GTPase activator activity,GO:0005096,Parkinson Disease,MESH:D010300,0,,2,DNM1L|LRRK2
GTPase activator activity,GO:0005096,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
GTPase activator activity,GO:0005096,"Parkinson Disease, Secondary",MESH:D010302,0,,1,RGS2
GTPase activator activity,GO:0005096,Parkinsonian Disorders,MESH:D020734,0,,2,ALDH1A1|LRRK2
GTPase activity,GO:0003924,Parkinson Disease,MESH:D010300,0,,4,CPR|DNM1L|LRRK2|RAB32
GTPase activity,GO:0003924,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
GTPase activity,GO:0003924,"Parkinson Disease, Secondary",MESH:D010302,0,,1,RGS2
GTPase activity,GO:0003924,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
GTPase activity,GO:0003924,"Parkinsonism, early onset with mental retardation",MESH:C537179,0,,1,RAB39B
GTPase activity,GO:0003924,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
GTP binding,GO:0005525,Parkinson Disease,MESH:D010300,0,,5,CPR|DNM1L|INSR|LRRK2|RAB32
GTP binding,GO:0005525,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
GTP binding,GO:0005525,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
GTP binding,GO:0005525,"Parkinsonism, early onset with mental retardation",MESH:C537179,0,,1,RAB39B
GTP binding,GO:0005525,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
GTP-dependent protein binding,GO:0030742,Parkinson Disease,MESH:D010300,0,,2,DNM1L|RAB32
GTP-dependent protein kinase activity,GO:0034211,Parkinson Disease,MESH:D010300,0,,1,LRRK2
GTP-dependent protein kinase activity,GO:0034211,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
GTP-dependent protein kinase activity,GO:0034211,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
guanyl-nucleotide exchange factor activity,GO:0005085,Parkinson Disease,MESH:D010300,0,,1,INSR
guanyl-nucleotide exchange factor activity,GO:0005085,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
H3K27me3 modified histone binding,GO:0061628,Parkinson Disease,MESH:D010300,4,"Fungicides, Industrial|Particulate Matter|Smoke|Vehicle Emissions",0,
H3K27me3 modified histone binding,GO:0061628,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
haptoglobin binding,GO:0031720,Parkinson Disease,MESH:D010300,0,,1,HBG1
heat shock protein binding,GO:0031072,Parkinson Disease,MESH:D010300,0,,6,HSC70-3|HSPA1A|HSPA9|MAPT|PRKN|SLC18A2
heat shock protein binding,GO:0031072,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
heat shock protein binding,GO:0031072,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
heat shock protein binding,GO:0031072,"Parkinson Disease, Secondary",MESH:D010302,0,,3,PRKN|SLC18A2|TFAM
heat shock protein binding,GO:0031072,Parkinsonian Disorders,MESH:D020734,0,,3,MAPT|PRKN|SLC18A2
heme binding,GO:0020037,Parkinson Disease,MESH:D010300,0,,5,CYP2D6|CYP2E1|HBG1|HMOX1|NOS1
heme binding,GO:0020037,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
heme oxygenase (decyclizing) activity,GO:0004392,Parkinson Disease,MESH:D010300,1,Rotenone,1,HMOX1
heme oxygenase (decyclizing) activity,GO:0004392,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
heme oxygenase (decyclizing) activity,GO:0004392,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
hemoglobin alpha binding,GO:0031721,Parkinson Disease,MESH:D010300,0,,1,HBG1
heparan sulfate proteoglycan binding,GO:0043395,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
hepatocyte growth factor receptor activity,GO:0005008,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
heterocyclic compound binding,GO:1901363,Parkinson Disease,MESH:D010300,0,,4,DRD1|DRD2|SLC18A2|SLC6A3
heterocyclic compound binding,GO:1901363,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SLC18A2
heterocyclic compound binding,GO:1901363,Parkinsonian Disorders,MESH:D020734,0,,2,DRD2|SLC18A2
heterocyclic compound binding,GO:1901363,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
heterotrimeric G-protein binding,GO:0032795,Parkinson Disease,MESH:D010300,0,,2,DRD1|DRD2
heterotrimeric G-protein binding,GO:0032795,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
hexokinase activity,GO:0004396,Parkinson Disease,MESH:D010300,4,Air Pollutants|Clozapine|Gabapentin|Particulate Matter,0,
hexokinase activity,GO:0004396,"Parkinson Disease, Secondary",MESH:D010302,3,Chlorpromazine|Diltiazem|Valproic Acid,0,
hexokinase activity,GO:0004396,Parkinsonian Disorders,MESH:D020734,5,Chlorpromazine|Clozapine|Indomethacin|Particulate Matter|Valproic Acid,0,
hexokinase activity,GO:0004396,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Diltiazem,0,
high-density lipoprotein particle binding,GO:0008035,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PON1
high voltage-gated calcium channel activity,GO:0008331,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
high voltage-gated calcium channel activity,GO:0008331,"Parkinson Disease, Secondary",MESH:D010302,1,Nifedipine,0,
high voltage-gated calcium channel activity,GO:0008331,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
histone acetyltransferase activity,GO:0004402,Parkinson Disease,MESH:D010300,1,Estradiol,0,
histone acetyltransferase activity,GO:0004402,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
histone acetyltransferase activity,GO:0004402,Parkinsonian Disorders,MESH:D020734,3,Curcumin|manganese chloride|Valproic Acid,0,
histone binding,GO:0042393,Parkinson Disease,MESH:D010300,0,,1,SNCA
histone binding,GO:0042393,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
histone binding,GO:0042393,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
histone binding,GO:0042393,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
histone binding,GO:0042393,Parkinsonian Disorders,MESH:D020734,0,,2,PARP1|SNCA
histone deacetylase activity,GO:0004407,Parkinson Disease,MESH:D010300,2,Endosulfan|Estradiol,0,
histone deacetylase activity,GO:0004407,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
histone deacetylase activity,GO:0004407,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Valproic Acid,0,
histone deacetylase activity,GO:0004407,Parkinsonian Disorders,MESH:D020734,3,Curcumin|Plant Extracts|Valproic Acid,0,
histone deacetylase binding,GO:0042826,Parkinson Disease,MESH:D010300,0,,3,HSPA1A|MTA1|PRKN
histone deacetylase binding,GO:0042826,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
histone deacetylase binding,GO:0042826,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
histone deacetylase binding,GO:0042826,Parkinsonian Disorders,MESH:D020734,0,,2,PARP1|PRKN
histone-dependent DNA binding,GO:0099077,Parkinson Disease,MESH:D010300,0,,1,MAPT
histone-dependent DNA binding,GO:0099077,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
histone-dependent DNA binding,GO:0099077,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
histone H2AS121 kinase activity,GO:0072371,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H2AS121 kinase activity,GO:0072371,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H2AS121 kinase activity,GO:0072371,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H2AS121 kinase activity,GO:0072371,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H2AS121 kinase activity,GO:0072371,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H2AS139 kinase activity,GO:0035979,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H2AS139 kinase activity,GO:0035979,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H2AS139 kinase activity,GO:0035979,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H2AS139 kinase activity,GO:0035979,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H2AS139 kinase activity,GO:0035979,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H2AS1 kinase activity,GO:0044024,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H2AS1 kinase activity,GO:0044024,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H2AS1 kinase activity,GO:0044024,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H2AS1 kinase activity,GO:0044024,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H2AS1 kinase activity,GO:0044024,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H2AT120 kinase activity,GO:1990244,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H2AT120 kinase activity,GO:1990244,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H2AT120 kinase activity,GO:1990244,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H2AT120 kinase activity,GO:1990244,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H2AT120 kinase activity,GO:1990244,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H2BS14 kinase activity,GO:0044025,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H2BS14 kinase activity,GO:0044025,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H2BS14 kinase activity,GO:0044025,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H2BS14 kinase activity,GO:0044025,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H2BS14 kinase activity,GO:0044025,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H2BS36 kinase activity,GO:0140823,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H2BS36 kinase activity,GO:0140823,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H2BS36 kinase activity,GO:0140823,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H2BS36 kinase activity,GO:0140823,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H2BS36 kinase activity,GO:0140823,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H2Y142 phosphatase activity,GO:0140793,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
histone H3K9 demethylase activity,GO:0032454,Parkinson Disease,MESH:D010300,2,Melatonin|Particulate Matter,0,
histone H3K9 demethylase activity,GO:0032454,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
histone H3K9 demethylase activity,GO:0032454,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Particulate Matter,0,
histone H3S10 kinase activity,GO:0035175,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H3S10 kinase activity,GO:0035175,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H3S10 kinase activity,GO:0035175,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H3S10 kinase activity,GO:0035175,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H3S10 kinase activity,GO:0035175,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H3S28 kinase activity,GO:0044022,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H3S28 kinase activity,GO:0044022,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H3S28 kinase activity,GO:0044022,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H3S28 kinase activity,GO:0044022,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H3S28 kinase activity,GO:0044022,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H3S57 kinase activity,GO:0140855,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H3S57 kinase activity,GO:0140855,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H3S57 kinase activity,GO:0140855,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H3S57 kinase activity,GO:0140855,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H3S57 kinase activity,GO:0140855,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H3T11 kinase activity,GO:0035402,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H3T11 kinase activity,GO:0035402,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H3T11 kinase activity,GO:0035402,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H3T11 kinase activity,GO:0035402,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H3T11 kinase activity,GO:0035402,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H3T3 kinase activity,GO:0072354,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H3T3 kinase activity,GO:0072354,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H3T3 kinase activity,GO:0072354,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H3T3 kinase activity,GO:0072354,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H3T3 kinase activity,GO:0072354,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H3T45 kinase activity,GO:0140857,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H3T45 kinase activity,GO:0140857,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H3T45 kinase activity,GO:0140857,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H3T45 kinase activity,GO:0140857,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H3T45 kinase activity,GO:0140857,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H3T6 kinase activity,GO:0035403,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H3T6 kinase activity,GO:0035403,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H3T6 kinase activity,GO:0035403,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H3T6 kinase activity,GO:0035403,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H3T6 kinase activity,GO:0035403,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
histone H4S1 kinase activity,GO:0044023,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
histone H4S1 kinase activity,GO:0044023,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
histone H4S1 kinase activity,GO:0044023,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
histone H4S1 kinase activity,GO:0044023,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
histone H4S1 kinase activity,GO:0044023,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
hormone activity,GO:0005179,Parkinson Disease,MESH:D010300,0,,3,EDN1|IGF2|INS
hormone activity,GO:0005179,Parkinsonian Disorders,MESH:D020734,0,,1,PRL
Hsp70 protein binding,GO:0030544,Parkinson Disease,MESH:D010300,0,,3,CYP2E1|PRKN|SNCA
Hsp70 protein binding,GO:0030544,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
Hsp70 protein binding,GO:0030544,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
Hsp70 protein binding,GO:0030544,"Parkinson Disease, Secondary",MESH:D010302,0,,2,PRKN|SNCA
Hsp70 protein binding,GO:0030544,Parkinsonian Disorders,MESH:D020734,0,,2,PRKN|SNCA
Hsp90 protein binding,GO:0051879,Parkinson Disease,MESH:D010300,0,,2,CYP2E1|MAPT
Hsp90 protein binding,GO:0051879,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
Hsp90 protein binding,GO:0051879,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
Hsp90 protein binding,GO:0051879,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
hydrolase activity,GO:0016787,Parkinson Disease,MESH:D010300,0,,5,DNM1L|FBP1|GBA1|PARK7|RDGA
hydrolase activity,GO:0016787,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
hydrolase activity,GO:0016787,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
hydrolase activity,GO:0016787,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
hydrolase activity,GO:0016787,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,ATXN3|GBA1
hydrolase activity,GO:0016787,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PON1
hydrolase activity,GO:0016787,Parkinsonian Disorders,MESH:D020734,0,,2,GBA1|PARK7
"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides",GO:0016812,"PARKINSON DISEASE 23, AUTOSOMAL RECESSIVE EARLY-ONSET",OMIM:616840,0,,1,VPS13C
"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides",GO:0016811,Parkinson Disease,MESH:D010300,0,,1,PARK7
"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides",GO:0016811,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides",GO:0016811,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
"hydrolase activity, acting on ester bonds",GO:0016788,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Permethrin,1,MAG
"hydrolase activity, acting on ester bonds",GO:0016788,"Parkinson Disease, Secondary",MESH:D010302,0,,1,BCHE
"hydrolase activity, acting on ester bonds",GO:0016788,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
"hydrolase activity, acting on glycosyl bonds",GO:0016798,Parkinson Disease,MESH:D010300,0,,1,GBA1
"hydrolase activity, acting on glycosyl bonds",GO:0016798,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
"hydrolase activity, acting on glycosyl bonds",GO:0016798,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
identical protein binding,GO:0042802,Parkinson Disease,MESH:D010300,0,,32,ALDH2|CEACAM6|DNM1L|DRD2|ENO2|FBP1|GFAP|GSTA4|GSTM1|HGF|HMOX1|IGF1R|IGF2R|IL6|INS|INSR|LRRK2|MAG|MAOB|MAP3K5|MAPT|NECTIN2|NOS1|NQO1|PARK7|PRKN|SNCA|SOD1|SOD2|TALDO1|TH|TNF
identical protein binding,GO:0042802,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
identical protein binding,GO:0042802,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
identical protein binding,GO:0042802,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
identical protein binding,GO:0042802,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
identical protein binding,GO:0042802,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
identical protein binding,GO:0042802,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
identical protein binding,GO:0042802,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,4,ADH1C|ATXN3|MAPT|SNCAIP
identical protein binding,GO:0042802,"Parkinson Disease, Secondary",MESH:D010302,0,,4,BCHE|NOS2|PRKN|SNCA
identical protein binding,GO:0042802,Parkinsonian Disorders,MESH:D020734,0,,14,ALDH1A1|DCTN1|DRD2|GAPDH|GSR|HTRA2|LRRK2|MAPT|PARK7|PARP1|PRKN|PRKRA|SNCA|TH
IgE binding,GO:0019863,Parkinson Disease,MESH:D010300,0,,1,FCER2
IkappaB kinase activity,GO:0008384,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
IkappaB kinase activity,GO:0008384,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
IMP dehydrogenase activity,GO:0003938,"Parkinson Disease, Secondary",MESH:D010302,1,Ribavirin,0,
"indoleamine 2,3-dioxygenase activity",GO:0033754,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
"indoleamine 2,3-dioxygenase activity",GO:0033754,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Lipopolysaccharides,0,
"inositol-1,4,5-trisphosphate 5-phosphatase activity",GO:0052658,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
inositol phosphate phosphatase activity,GO:0052745,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
insulin binding,GO:0043559,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
insulin-like growth factor binding,GO:0005520,Parkinson Disease,MESH:D010300,0,,2,IGF1R|IGF2R
insulin-like growth factor I binding,GO:0031994,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
insulin-like growth factor II binding,GO:0031995,Parkinson Disease,MESH:D010300,0,,2,IGF2R|INSR
insulin-like growth factor receptor activity,GO:0005010,Parkinson Disease,MESH:D010300,0,,3,IGF1R|IGF2R|INSR
insulin-like growth factor receptor binding,GO:0005159,Parkinson Disease,MESH:D010300,0,,3,IGF2|INS|INSR
insulin receptor activity,GO:0005009,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
insulin receptor binding,GO:0005158,Parkinson Disease,MESH:D010300,0,,3,IGF1R|IGF2|INS
insulin receptor substrate binding,GO:0043560,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
insulin receptor substrate binding,GO:0043560,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
integrin binding,GO:0005178,Parkinson Disease,MESH:D010300,0,,3,FCER2|GFAP|IGF2
interleukin-6 receptor binding,GO:0005138,Parkinson Disease,MESH:D010300,0,,1,IL6
intracellular cAMP-activated cation channel activity,GO:0005222,Parkinson Disease,MESH:D010300,1,Sirolimus,0,
inward rectifier potassium channel activity,GO:0005242,Parkinson Disease,MESH:D010300,0,,1,KCNJ4
inward rectifier potassium channel activity,GO:0005242,"Parkinson Disease, Secondary",MESH:D010302,2,Cisapride|Verapamil,0,
inward rectifier potassium channel activity,GO:0005242,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
ionotropic glutamate receptor binding,GO:0035255,Parkinson Disease,MESH:D010300,0,,1,DRD2
ionotropic glutamate receptor binding,GO:0035255,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
iron ion binding,GO:0005506,Parkinson Disease,MESH:D010300,0,,3,CYP2D6|CYP2E1|TH
iron ion binding,GO:0005506,Parkinsonian Disorders,MESH:D020734,1,Cadmium,2,CAT-2|TH
iron ion transmembrane transporter activity,GO:0005381,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
iron-sulfur cluster binding,GO:0051536,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
iron-sulfur cluster binding,GO:0051536,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
iron-sulfur cluster binding,GO:0051536,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
isocitrate dehydrogenase (NAD+) activity,GO:0004449,Parkinson Disease,MESH:D010300,1,Zinc,0,
isocitrate dehydrogenase (NADP+) activity,GO:0004450,Parkinson Disease,MESH:D010300,2,Acrolein|Zinc,0,
isocitrate dehydrogenase [NAD(P)+] activity,GO:0004448,Parkinson Disease,MESH:D010300,2,Copper|Iron,0,
isocitrate dehydrogenase [NAD(P)+] activity,GO:0004448,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
isocitrate dehydrogenase [NAD(P)+] activity,GO:0004448,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
isocitrate dehydrogenase [NAD(P)+] activity,GO:0004448,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
JUN kinase activity,GO:0004705,Parkinson Disease,MESH:D010300,2,1-Methyl-4-phenylpyridinium|Lipopolysaccharides,0,
JUN kinase activity,GO:0004705,Parkinsonian Disorders,MESH:D020734,4,1-Methyl-4-phenylpyridinium|Cadmium|Docosahexaenoic Acids|Lipopolysaccharides,0,
JUN kinase binding,GO:0008432,Parkinson Disease,MESH:D010300,0,,1,GSTP1
JUN kinase kinase kinase activity,GO:0004706,Parkinson Disease,MESH:D010300,0,,2,LRRK2|MAP3K5
JUN kinase kinase kinase activity,GO:0004706,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
JUN kinase kinase kinase activity,GO:0004706,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
K48-linked deubiquitinase activity,GO:1990380,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
K63-linked deubiquitinase activity,GO:0061578,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
kinase activity,GO:0016301,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
kinase activity,GO:0016301,Parkinson Disease,MESH:D010300,0,,4,GAK|LRRK2|MAP3K5|PINK1
kinase activity,GO:0016301,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
kinase activity,GO:0016301,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
kinase activity,GO:0016301,Parkinsonian Disorders,MESH:D020734,0,,3,LRRK2|PINK1|PRKRA
kinase activity,GO:0016301,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
kinase binding,GO:0019900,Parkinson Disease,MESH:D010300,0,,4,GFAP|PARK7|PINK1|PRKN
kinase binding,GO:0019900,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
kinase binding,GO:0019900,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
kinase binding,GO:0019900,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
kinase binding,GO:0019900,Parkinsonian Disorders,MESH:D020734,0,,3,PARK7|PINK1|PRKN
kinase regulator activity,GO:0019207,Parkinson Disease,MESH:D010300,0,,1,GSTP1
kinesin binding,GO:0019894,Parkinson Disease,MESH:D010300,0,,1,SNCA
kinesin binding,GO:0019894,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
kinesin binding,GO:0019894,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
kinesin binding,GO:0019894,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
kinesin binding,GO:0019894,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
lactase activity,GO:0000016,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
lactase activity,GO:0000016,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
lactate dehydrogenase activity,GO:0004457,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
lactate dehydrogenase activity,GO:0004457,Parkinson Disease,MESH:D010300,25,"1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Air Pollutants|Atrazine|beta-N-methylamino-L-alanine|Caffeine|carbidopa, levodopa drug combination|Carbon Tetrachloride|Chlorpyrifos|Clozapine|Endosulfan|Homocysteine|Lead|Lipopolysaccharides|Maneb|Manganese|Oxidopamine|Ozone|Paraquat|Particulate Matter|Permethrin|Rotenone|Sirolimus|Trichloroethylene|Zinc",0,
lactate dehydrogenase activity,GO:0004457,"Parkinson Disease, Secondary",MESH:D010302,21,"3-methyladenine|Atrazine|Benzo(a)pyrene|carbidopa, levodopa drug combination|Cimetidine|Doxorubicin|geraniol|Maneb|Manganese|Methotrexate|Nicotine|Oxidopamine|Paraquat|PQQ Cofactor|Resveratrol|Rotenone|Silymarin|thymoquinone|Trichloroethylene|Valproic Acid|Venlafaxine Hydrochloride",0,
lactate dehydrogenase activity,GO:0004457,Parkinsonian Disorders,MESH:D020734,24,"1-Methyl-4-phenylpyridinium|baicalin|Cadmium|carbidopa, levodopa drug combination|Clozapine|coenzyme Q10|crocin|Curcumin|cypermethrin|geraniol|Lipopolysaccharides|Maneb|Manganese|manganese chloride|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Resveratrol|Rotenone|Silymarin|taxifolin|Valproic Acid",0,
lactate dehydrogenase activity,GO:0004457,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
L-alanine:2-oxoglutarate aminotransferase activity,GO:0004021,Parkinson Disease,MESH:D010300,2,Lead|Pyridoxine,0,
L-alanine:2-oxoglutarate aminotransferase activity,GO:0004021,"Parkinson Disease, Secondary",MESH:D010302,3,geraniol|Pyridoxine|Silymarin,0,
L-alanine:2-oxoglutarate aminotransferase activity,GO:0004021,Parkinsonian Disorders,MESH:D020734,3,geraniol|Plant Extracts|Silymarin,0,
laminin-1 binding,GO:0043237,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
large conductance calcium-activated potassium channel activity,GO:0060072,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
large ribosomal subunit rRNA binding,GO:0070180,Parkinson Disease,MESH:D010300,0,,1,RPL23A
L-aspartate:2-oxoglutarate aminotransferase activity,GO:0004069,Parkinson Disease,MESH:D010300,24,4-phenylbutyric acid|Atrazine|Caffeine|Carbidopa|Carbon Tetrachloride|Chlorpyrifos|Herbicides|Homocysteine|Iron|Ketoconazole|Lead|Lipopolysaccharides|mangiferin|Melatonin|Methomyl|Ozone|Paraquat|pendimethalin|Permethrin|Pioglitazone|Rotenone|Sirolimus|Tranylcypromine|Zinc,0,
L-aspartate:2-oxoglutarate aminotransferase activity,GO:0004069,"Parkinson Disease, Secondary",MESH:D010302,18,3-methyladenine|Amlodipine|Atrazine|Benzo(a)pyrene|Carbidopa|Cimetidine|Doxorubicin|geraniol|Melatonin|Methotrexate|Nicotine|Paraquat|Paroxetine|Resveratrol|Rotenone|Silymarin|thymoquinone|Vincristine,0,
L-aspartate:2-oxoglutarate aminotransferase activity,GO:0004069,Parkinsonian Disorders,MESH:D020734,24,6-methyl-2-(phenylethynyl)pyridine|Amlodipine|baicalin|Cadmium|Carbidopa|coenzyme Q10|crocin|Curcumin|cypermethrin|Docosahexaenoic Acids|geraniol|Ketoconazole|Lipopolysaccharides|Melatonin|Muscimol|Paraquat|Paroxetine|Permethrin|Plant Extracts|Resveratrol|Rotenone|Silymarin|taxifolin|Zidovudine,0,
L-aspartate:2-oxoglutarate aminotransferase activity,GO:0004069,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
L-dopa decarboxylase activator activity,GO:0036478,Parkinson Disease,MESH:D010300,0,,1,PARK7
L-dopa decarboxylase activator activity,GO:0036478,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
L-dopa decarboxylase activator activity,GO:0036478,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
L-dopa decarboxylase activity,GO:0036468,Parkinson Disease,MESH:D010300,0,,1,DDC
L-dopa decarboxylase activity,GO:0036468,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
L-glutamine transmembrane transporter activity,GO:0015186,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
ligand-gated calcium channel activity,GO:0099604,Parkinson Disease,MESH:D010300,0,,1,TRPM2
ligand-gated monoatomic cation channel activity,GO:0099094,Parkinson Disease,MESH:D010300,0,,1,TRPM2
ligand-gated monoatomic ion channel activity,GO:0015276,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
ligand-gated monoatomic ion channel activity,GO:0015276,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
ligase activity,GO:0016874,Parkinson Disease,MESH:D010300,0,,1,PRKN
ligase activity,GO:0016874,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
ligase activity,GO:0016874,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
lipase activity,GO:0016298,Parkinson Disease,MESH:D010300,1,Ozone,0,
lipase activity,GO:0016298,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
lipid binding,GO:0008289,Parkinson Disease,MESH:D010300,0,,3,DNM1L|NGF|SNCA
lipid binding,GO:0008289,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
lipid binding,GO:0008289,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
lipid binding,GO:0008289,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
lipid binding,GO:0008289,Parkinsonian Disorders,MESH:D020734,0,,2,NGF|SNCA
lipid transporter activity,GO:0005319,Parkinson Disease,MESH:D010300,0,,1,MAG
lipoic acid binding,GO:0031405,Parkinson Disease,MESH:D010300,0,,1,INSR
lipoprotein particle binding,GO:0071813,Parkinson Disease,MESH:D010300,0,,1,MAPT
lipoprotein particle binding,GO:0071813,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
lipoprotein particle binding,GO:0071813,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
L-lactate dehydrogenase activity,GO:0004459,Parkinson Disease,MESH:D010300,1,"Water Pollutants, Chemical",0,
lncRNA binding,GO:0106222,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
long-chain acyl-CoA hydrolase activity,GO:0052816,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
long-chain fatty acid omega-1 hydroxylase activity,GO:0120319,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
low-affinity IgE receptor activity,GO:0019769,Parkinson Disease,MESH:D010300,0,,1,FCER2
L-serine transmembrane transporter activity,GO:0015194,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
lyase activity,GO:0016829,Parkinson Disease,MESH:D010300,0,,2,DDC|ENO2
lyase activity,GO:0016829,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
lysine-acetylated histone binding,GO:0070577,Parkinson Disease,MESH:D010300,2,"Fungicides, Industrial|Manganese",0,
lysine-acetylated histone binding,GO:0070577,"Parkinson Disease, Secondary",MESH:D010302,3,Manganese|Nicotine|Valproic Acid,0,
lysine-acetylated histone binding,GO:0070577,Parkinsonian Disorders,MESH:D020734,3,Manganese|manganese chloride|Valproic Acid,0,
lysophospholipase activity,GO:0004622,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
macrophage colony-stimulating factor receptor activity,GO:0005011,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
magnesium ion binding,GO:0000287,Parkinson Disease,MESH:D010300,0,,5,ENO2|LRRK2|MAP3K5|PINK1|SNCA
magnesium ion binding,GO:0000287,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
magnesium ion binding,GO:0000287,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
magnesium ion binding,GO:0000287,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
magnesium ion binding,GO:0000287,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
magnesium ion binding,GO:0000287,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
magnesium ion binding,GO:0000287,Parkinsonian Disorders,MESH:D020734,0,,3,LRRK2|PINK1|SNCA
magnesium ion transmembrane transporter activity,GO:0015095,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
malate dehydrogenase activity,GO:0016615,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
malate dehydrogenase activity,GO:0016615,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|thymoquinone,0,
malate dehydrogenase activity,GO:0016615,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Curcumin|Particulate Matter,0,
malate dehydrogenase activity,GO:0016615,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
malic enzyme activity,GO:0004470,Parkinson Disease,MESH:D010300,2,Copper|Zinc,0,
malic enzyme activity,GO:0004470,"Parkinson Disease, Secondary",MESH:D010302,1,thymoquinone,0,
maltose alpha-glucosidase activity,GO:0032450,Parkinson Disease,MESH:D010300,1,Paraquat,0,
maltose alpha-glucosidase activity,GO:0032450,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
maltose alpha-glucosidase activity,GO:0032450,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
manganese ion binding,GO:0030145,Parkinson Disease,MESH:D010300,0,,2,ATP13A2|SOD2
manganese ion binding,GO:0030145,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
manganese ion binding,GO:0030145,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
manganese ion transmembrane transporter activity,GO:0005384,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
manganese ion transmembrane transporter activity,GO:0005384,Parkinson Disease,MESH:D010300,0,,2,SLC30A10|TRPM2
manganese ion transmembrane transporter activity,GO:0005384,Parkinsonian Disorders,MESH:D020734,0,,1,SLC30A10
mannose binding,GO:0005537,Parkinson Disease,MESH:D010300,0,,1,IGF2R
MAP kinase activity,GO:0004707,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
MAP kinase kinase kinase activity,GO:0004709,Parkinson Disease,MESH:D010300,0,,2,LRRK2|MAP3K5
MAP kinase kinase kinase activity,GO:0004709,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
MAP kinase kinase kinase activity,GO:0004709,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
membrane scission GTPase motor activity,GO:1990606,Parkinson Disease,MESH:D010300,0,,1,DNM1L
mercury ion binding,GO:0045340,Parkinson Disease,MESH:D010300,0,,1,PARK7
mercury ion binding,GO:0045340,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
mercury ion binding,GO:0045340,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
metal ion binding,GO:0046872,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
metal ion binding,GO:0046872,Parkinson Disease,MESH:D010300,0,,23,ADARB2|AIF1|ATP13A2|CP|CYP2D6|ENO2|FBP1|FCER2|HBG1|HMOX1|HSC70-3|MAP3K5|MTA1|NOS1|PINK1|PRKN|RDGA|SLC6A3|SNCA|SOD1|SOD2|TH|TRPM2
metal ion binding,GO:0046872,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
metal ion binding,GO:0046872,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
metal ion binding,GO:0046872,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
metal ion binding,GO:0046872,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,ADH1C|NR4A2
metal ion binding,GO:0046872,"Parkinson Disease, Secondary",MESH:D010302,0,,6,ATP13A2|NOS2|PON1|PRKN|SHH|SNCA
metal ion binding,GO:0046872,Parkinsonian Disorders,MESH:D020734,0,,10,ATP13A2|ATP1A3|CAT-2|PARP1|PINK1|POLG|PRKN|PRL|SNCA|TH
metal ion binding,GO:0046872,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
metal ion transmembrane transporter activity,GO:0046873,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
metallocarboxypeptidase activity,GO:0004181,Parkinson Disease,MESH:D010300,0,,1,VPS35
metallocarboxypeptidase activity,GO:0004181,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
metalloendopeptidase activity,GO:0004222,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
metalloendopeptidase inhibitor activity,GO:0008191,Parkinson Disease,MESH:D010300,0,,1,NGF
metalloendopeptidase inhibitor activity,GO:0008191,Parkinsonian Disorders,MESH:D020734,0,,1,NGF
methylated histone binding,GO:0035064,Parkinson Disease,MESH:D010300,3,"Fungicides, Industrial|Particulate Matter|Vehicle Emissions",1,NCAPG2
methylated histone binding,GO:0035064,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
methylenetetrahydrofolate reductase (NAD(P)H) activity,GO:0004489,Parkinson Disease,MESH:D010300,0,,1,MTHFR
methylenetetrahydrofolate reductase NADPH activity,GO:0106313,Parkinson Disease,MESH:D010300,0,,1,MTHFR
methyltransferase activity,GO:0008168,Parkinson Disease,MESH:D010300,1,Ozone,0,
methyltransferase activity,GO:0008168,Parkinsonian Disorders,MESH:D020734,0,,1,PRL
MHC class II receptor activity,GO:0032395,Parkinson Disease,MESH:D010300,0,,1,HLA-DRA
microfilament motor activity,GO:0000146,Parkinson Disease,MESH:D010300,0,,1,PRM
microtubule binding,GO:0008017,Parkinson Disease,MESH:D010300,0,,6,DNM1L|KST|LRRK2|MAP2|MAPT|SNCA
microtubule binding,GO:0008017,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
microtubule binding,GO:0008017,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
microtubule binding,GO:0008017,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
microtubule binding,GO:0008017,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
microtubule binding,GO:0008017,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
microtubule binding,GO:0008017,Parkinsonian Disorders,MESH:D020734,0,,5,DCTN1|GAPDH|LRRK2|MAPT|SNCA
microtubule lateral binding,GO:0099609,Parkinson Disease,MESH:D010300,0,,1,MAPT
microtubule lateral binding,GO:0099609,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
microtubule lateral binding,GO:0099609,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
microtubule plus-end binding,GO:0051010,Parkinsonian Disorders,MESH:D020734,0,,1,DCTN1
microtubule severing ATPase activity,GO:0008568,Parkinson Disease,MESH:D010300,0,,1,DDC
microtubule severing ATPase activity,GO:0008568,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
minor groove of adenine-thymine-rich DNA binding,GO:0003680,Parkinson Disease,MESH:D010300,0,,1,MAPT
minor groove of adenine-thymine-rich DNA binding,GO:0003680,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
minor groove of adenine-thymine-rich DNA binding,GO:0003680,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
misfolded protein binding,GO:0051787,Parkinson Disease,MESH:D010300,0,,3,HSC70-3|HSPA1A|HSPA9
mitochondrial promoter sequence-specific DNA binding,GO:0001018,"Parkinson Disease, Secondary",MESH:D010302,0,,1,TFAM
mitochondrial protein-transporting ATPase activity,GO:0008566,Parkinson Disease,MESH:D010300,1,Rotenone,0,
mitochondrial protein-transporting ATPase activity,GO:0008566,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
mitochondrial protein-transporting ATPase activity,GO:0008566,Parkinsonian Disorders,MESH:D020734,2,oleuropein|Rotenone,0,
mitochondrial transcription factor activity,GO:0034246,"Parkinson Disease, Secondary",MESH:D010302,0,,1,TFAM
modified amino acid binding,GO:0072341,Parkinson Disease,MESH:D010300,0,,1,MTHFR
molecular adaptor activity,GO:0060090,Parkinson Disease,MESH:D010300,0,,2,DRAXIN|SNCA
molecular adaptor activity,GO:0060090,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
molecular adaptor activity,GO:0060090,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
molecular adaptor activity,GO:0060090,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
molecular adaptor activity,GO:0060090,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
molecular adaptor activity,GO:0060090,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
molecular adaptor activity,GO:0060090,Parkinsonian Disorders,MESH:D020734,0,,2,DCTN1|SNCA
molecular_function,GO:0003674,Parkinson Disease,MESH:D010300,0,,2,MIR181C|TMEM230
molecular_function,GO:0003674,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
molecular_function,GO:0003674,"PARKINSON DISEASE 23, AUTOSOMAL RECESSIVE EARLY-ONSET",OMIM:616840,0,,1,VPS13C
molecular_function,GO:0003674,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,SNCAIP
molecular_function,GO:0003674,"Parkinson Disease, Mitochondrial",MESH:C564015,0,,1,FMC1
molecular_function,GO:0003674,"Parkinson Disease, Secondary",MESH:D010302,0,,1,FMC1
mono-ADP-D-ribose binding,GO:0072571,Parkinson Disease,MESH:D010300,0,,1,TRPM2
monoamine oxidase activity,GO:0097621,Parkinson Disease,MESH:D010300,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Aluminum|Rotenone",2,MAOA|MAOB
monoamine oxidase activity,GO:0097621,"Parkinson Disease, Secondary",MESH:D010302,2,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Rotenone",0,
monoamine oxidase activity,GO:0097621,Parkinsonian Disorders,MESH:D020734,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Cadmium|Rotenone|taxifolin",0,
monoamine:proton antiporter activity,GO:0015311,Parkinson Disease,MESH:D010300,0,,1,SLC18A2
monoamine:proton antiporter activity,GO:0015311,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SLC18A2
monoamine:proton antiporter activity,GO:0015311,Parkinsonian Disorders,MESH:D020734,0,,1,SLC18A2
monoamine transmembrane transporter activity,GO:0008504,Parkinson Disease,MESH:D010300,0,,2,SLC18A2|SLC6A3
monoamine transmembrane transporter activity,GO:0008504,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SLC18A2
monoamine transmembrane transporter activity,GO:0008504,Parkinsonian Disorders,MESH:D020734,0,,1,SLC18A2
monoamine transmembrane transporter activity,GO:0008504,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
monoatomic anion:monoatomic cation symporter activity,GO:0015296,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
monoatomic cation channel activity,GO:0005261,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
monoatomic cation channel activity,GO:0005261,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,1,TRPM2
monoatomic cation channel activity,GO:0005261,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
monoatomic cation transmembrane transporter activity,GO:0008324,Parkinson Disease,MESH:D010300,0,,1,SLC30A10
monoatomic cation transmembrane transporter activity,GO:0008324,Parkinsonian Disorders,MESH:D020734,0,,1,SLC30A10
monoatomic ion channel activity,GO:0005216,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
monoatomic ion channel activity,GO:0005216,Parkinson Disease,MESH:D010300,0,,1,TRPM2
monoatomic ion channel activity,GO:0005216,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
monooxygenase activity,GO:0004497,Parkinson Disease,MESH:D010300,0,,3,CYP2D6|CYP2E1|TH
monooxygenase activity,GO:0004497,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Sulpiride,0,
monooxygenase activity,GO:0004497,Parkinsonian Disorders,MESH:D020734,0,,2,CAT-2|TH
monosaccharide binding,GO:0048029,Parkinson Disease,MESH:D010300,0,,2,FBP1|TALDO1
morphogen activity,GO:0016015,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
mRNA base-pairing translational repressor activity,GO:1903231,Parkinson Disease,MESH:D010300,0,,1,MIR181C
mRNA binding,GO:0003729,Parkinson Disease,MESH:D010300,0,,2,PARK7|RPL6
mRNA binding,GO:0003729,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
mRNA binding,GO:0003729,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
mRNA binding,GO:0003729,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN2
mRNA binding,GO:0003729,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
myosin binding,GO:0017022,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
myosin V binding,GO:0031489,"Parkinsonism, early onset with mental retardation",MESH:C537179,0,,1,RAB39B
N-acetyltransferase activity,GO:0008080,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
NAD+ ADP-ribosyltransferase activity,GO:0003950,Parkinson Disease,MESH:D010300,1,Paraquat,0,
NAD+ ADP-ribosyltransferase activity,GO:0003950,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
NAD+ ADP-ribosyltransferase activity,GO:0003950,Parkinsonian Disorders,MESH:D020734,1,Paraquat,1,PARP1
NAD binding,GO:0051287,Parkinson Disease,MESH:D010300,0,,2,ALDH2|GPDH1
NAD binding,GO:0051287,Parkinsonian Disorders,MESH:D020734,0,,3,ALDH1A1|GAPDH|PARP1
NAD DNA ADP-ribosyltransferase activity,GO:0140294,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NADH binding,GO:0070404,Parkinson Disease,MESH:D010300,0,,1,ALDH2
NADH dehydrogenase activity,GO:0003954,Parkinson Disease,MESH:D010300,2,"Lead|Water Pollutants, Chemical",0,
NADH dehydrogenase activity,GO:0003954,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
NADH dehydrogenase activity,GO:0003954,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
NADH dehydrogenase (quinone) activity,GO:0050136,Parkinson Disease,MESH:D010300,0,,1,NQO1
NADH dehydrogenase (ubiquinone) activity,GO:0008137,Parkinson Disease,MESH:D010300,24,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Air Pollutants|Atrazine|Clozapine|Eicosapentaenoic Acid|Lead|Levodopa|Lipopolysaccharides|Lithium|Maneb|Minocycline|Nitrites|Oxidopamine|Ozone|Paraquat|Particulate Matter|Rotenone|Selegiline|Sirolimus|Soot|Vehicle Emissions",0,
NADH dehydrogenase (ubiquinone) activity,GO:0008137,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
NADH dehydrogenase (ubiquinone) activity,GO:0008137,"Parkinson Disease, Secondary",MESH:D010302,16,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Atrazine|Chlorpromazine|Exenatide|Haloperidol|Levodopa|Lithium|Maneb|Minocycline|Oxidopamine|Paraquat|Resveratrol|Risperidone|Rotenone|Valproic Acid",0,
NADH dehydrogenase (ubiquinone) activity,GO:0008137,Parkinsonian Disorders,MESH:D020734,27,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|annonacin|Bupropion|Cadmium|Chlorpromazine|Clozapine|coenzyme Q10|Curcumin|cypermethrin|Docosahexaenoic Acids|ginsenoside Re|Haloperidol|Levodopa|Lipopolysaccharides|Maneb|oleuropein|Oxidopamine|Paraquat|Particulate Matter|Plant Extracts|Resveratrol|Risperidone|Rotenone|Selegiline|taxifolin|Valproic Acid",0,
NADH dehydrogenase (ubiquinone) activity,GO:0008137,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Lithium,0,
NAD+-histone H2BE18 glutamate ADP-ribosyltransferase activity,GO:0140867,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD+-histone H2BE2 glutamate ADP-ribosyltransferase activity,GO:0140844,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD+-histone H2BE35 glutamate ADP-ribosyltransferase activity,GO:0140822,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD+-histone H2BS6 serine ADP-ribosyltransferase activity,GO:0140816,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD+-histone H3S10 serine ADP-ribosyltransferase activity,GO:0140817,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD+ nucleosidase activity,GO:0003953,Parkinson Disease,MESH:D010300,0,,1,BST1
"NAD+ nucleotidase, cyclic ADP-ribose generating",GO:0061809,Parkinson Disease,MESH:D010300,0,,1,BST1
NADP binding,GO:0050661,Parkinson Disease,MESH:D010300,0,,2,MTHFR|NOS1
NADP binding,GO:0050661,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
NADP binding,GO:0050661,Parkinsonian Disorders,MESH:D020734,0,,2,GAPDH|GSR
NADPH binding,GO:0070402,Parkinson Disease,MESH:D010300,0,,1,NOS1
NADPH dehydrogenase activity,GO:0003959,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
NAD(P)H dehydrogenase (quinone) activity,GO:0003955,Parkinson Disease,MESH:D010300,0,,1,NQO1
NADPH dehydrogenase (quinone) activity,GO:0008753,Parkinson Disease,MESH:D010300,1,Endosulfan,1,NQO1
NADPH-hemoprotein reductase activity,GO:0003958,Parkinson Disease,MESH:D010300,0,,1,CPR
NADPH-hemoprotein reductase activity,GO:0003958,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
NAD(P)H oxidase H2O2-forming activity,GO:0016174,Parkinson Disease,MESH:D010300,5,Air Pollutants|Lead|Lipopolysaccharides|Particulate Matter|Rotenone,0,
NAD(P)H oxidase H2O2-forming activity,GO:0016174,"Parkinson Disease, Secondary",MESH:D010302,3,Nicotine|Resveratrol|Rotenone,0,
NAD(P)H oxidase H2O2-forming activity,GO:0016174,Parkinsonian Disorders,MESH:D020734,4,Lipopolysaccharides|Particulate Matter|Resveratrol|Rotenone,0,
NADPH:quinone reductase activity,GO:0003960,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
NADPH:quinone reductase activity,GO:0003960,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
NAD+-protein ADP-ribosyltransferase activity,GO:1990404,Parkinsonian Disorders,MESH:D020734,1,manganese chloride,1,PARP1
NAD+- protein-aspartate ADP-ribosyltransferase activity,GO:0140806,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD+-protein-glutamate ADP-ribosyltransferase activity,GO:0140807,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD+-protein-histidine ADP-ribosyltransferase activity,GO:0140815,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD+-protein-serine ADP-ribosyltransferase activity,GO:0140805,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD+-protein-tyrosine ADP-ribosyltransferase activity,GO:0140808,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
NAD-retinol dehydrogenase activity,GO:0004745,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ADH1C
nerve growth factor receptor binding,GO:0005163,Parkinson Disease,MESH:D010300,0,,2,BDNF|NGF
nerve growth factor receptor binding,GO:0005163,Parkinsonian Disorders,MESH:D020734,0,,1,NGF
neuropeptide hormone activity,GO:0005184,Parkinsonian Disorders,MESH:D020734,0,,2,PDYN|PNOC
neurotransmitter transmembrane transporter activity,GO:0005326,Parkinson Disease,MESH:D010300,0,,1,SLC6A3
neurotransmitter transmembrane transporter activity,GO:0005326,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
neurotrophin TRKB receptor binding,GO:0005169,Parkinson Disease,MESH:D010300,0,,1,BDNF
neutral L-amino acid:sodium symporter activity,GO:0005295,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
neutral L-amino acid transmembrane transporter activity,GO:0015175,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
NF-kappaB binding,GO:0051059,Parkinson Disease,MESH:D010300,2,Dicamba|Lipopolysaccharides,1,HSPA1A
NF-kappaB binding,GO:0051059,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
nickel cation binding,GO:0016151,Parkinson Disease,MESH:D010300,0,,1,GSTM1
nitric oxide binding,GO:0070026,Parkinson Disease,MESH:D010300,0,,1,GSTP1
nitric-oxide synthase activity,GO:0004517,Parkinson Disease,MESH:D010300,4,1-Methyl-4-phenylpyridinium|Caffeine|Methamphetamine|Paraquat,1,NOS1
nitric-oxide synthase activity,GO:0004517,"Parkinson Disease, Secondary",MESH:D010302,4,Doxorubicin|Methamphetamine|Paraquat|Resveratrol,1,NOS2
nitric-oxide synthase activity,GO:0004517,Parkinsonian Disorders,MESH:D020734,4,1-Methyl-4-phenylpyridinium|Cadmium|Paraquat|Resveratrol,0,
nitric-oxide synthase activity,GO:0004517,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
nitric-oxide synthase binding,GO:0050998,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
NMDA glutamate receptor activity,GO:0004972,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
NMDA glutamate receptor activity,GO:0004972,Parkinson Disease,MESH:D010300,1,beta-N-methylamino-L-alanine,0,
non-membrane spanning protein tyrosine kinase activity,GO:0004715,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
non-membrane spanning protein tyrosine phosphatase activity,GO:0004726,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
norepinephrine:sodium symporter activity,GO:0005334,Parkinson Disease,MESH:D010300,0,,1,SLC6A3
norepinephrine:sodium symporter activity,GO:0005334,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
nuclear androgen receptor binding,GO:0050681,Parkinson Disease,MESH:D010300,0,,1,PARK7
nuclear androgen receptor binding,GO:0050681,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
nuclear androgen receptor binding,GO:0050681,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
nuclear estrogen receptor activity,GO:0030284,Parkinson Disease,MESH:D010300,1,Estradiol,0,
nuclear estrogen receptor binding,GO:0030331,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
nuclear estrogen receptor binding,GO:0030331,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
nuclear glucocorticoid receptor binding,GO:0035259,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
nuclear receptor activity,GO:0004879,Parkinson Disease,MESH:D010300,1,Estradiol,0,
nuclear receptor activity,GO:0004879,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
nuclear receptor binding,GO:0016922,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
nuclear receptor coactivator activity,GO:0030374,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
nuclear retinoid X receptor binding,GO:0046965,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
nucleic acid binding,GO:0003676,Parkinson Disease,MESH:D010300,0,,5,CHP|CNTNAP2|CPR|PPARGC1A|RDGA
nucleic acid binding,GO:0003676,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
nucleosome binding,GO:0031491,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
nucleotidase activity,GO:0008252,Parkinsonian Disorders,MESH:D020734,1,manganese chloride,0,
nucleotide binding,GO:0000166,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
nucleotide binding,GO:0000166,Parkinson Disease,MESH:D010300,0,,6,ATP13A2|DNM1L|HSPA9|LRRK2|MAP3K5|PINK1
nucleotide binding,GO:0000166,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
nucleotide binding,GO:0000166,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
nucleotide binding,GO:0000166,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
nucleotide binding,GO:0000166,Parkinsonian Disorders,MESH:D020734,0,,5,ATP13A2|GAPDH|GSR|LRRK2|PINK1
nucleotidyltransferase activity,GO:0016779,Parkinsonian Disorders,MESH:D020734,0,,2,PARP1|POLG
nutrient reservoir activity,GO:0045735,Parkinson Disease,MESH:D010300,3,Air Pollutants|Particulate Matter|pendimethalin,1,FBP1
nutrient reservoir activity,GO:0045735,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
odorant binding,GO:0005549,Parkinson Disease,MESH:D010300,0,,1,OBP99B
omega peptidase activity,GO:0008242,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
opioid peptide activity,GO:0001515,Parkinsonian Disorders,MESH:D020734,0,,2,PDYN|PNOC
opioid receptor binding,GO:0031628,Parkinsonian Disorders,MESH:D020734,0,,2,PDYN|PNOC
organic acid binding,GO:0043177,Parkinson Disease,MESH:D010300,0,,1,HBG1
ornithine carbamoyltransferase activity,GO:0004585,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
oxidoreductase activity,GO:0016491,Parkinson Disease,MESH:D010300,0,,13,ALDH2|CP|CPR|CYP2D6|CYP2E1|MAOA|MAOB|MTHFR|NOS1|SNCA|SOD1|SOD2|TH
oxidoreductase activity,GO:0016491,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
oxidoreductase activity,GO:0016491,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
oxidoreductase activity,GO:0016491,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ADH1C
oxidoreductase activity,GO:0016491,"Parkinson Disease, Secondary",MESH:D010302,0,,2,NOS2|SNCA
oxidoreductase activity,GO:0016491,Parkinsonian Disorders,MESH:D020734,0,,6,ALDH1A1|ALDH1A2|GAPDH|GSR|SNCA|TH
"oxidoreductase activity, acting on a sulfur group of donors, NAD(P) as acceptor",GO:0016668,Parkinsonian Disorders,MESH:D020734,0,,1,GSR
"oxidoreductase activity, acting on metal ions, oxygen as acceptor",GO:0016724,Parkinson Disease,MESH:D010300,0,,1,CP
"oxidoreductase activity, acting on NAD(P)H",GO:0016651,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
"oxidoreductase activity, acting on NAD(P)H",GO:0016651,Parkinsonian Disorders,MESH:D020734,2,Curcumin|geraniol,0,
"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen",GO:0016705,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen",GO:0016709,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen",GO:0016712,Parkinson Disease,MESH:D010300,0,,2,CYP2D6|CYP2E1
"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen",GO:0016712,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|geraniol,0,
"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen",GO:0016712,Parkinsonian Disorders,MESH:D020734,2,geraniol|manganese chloride,0,
"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen",GO:0016714,Parkinson Disease,MESH:D010300,0,,1,TH
"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen",GO:0016714,Parkinsonian Disorders,MESH:D020734,0,,2,CAT-2|TH
"oxidoreductase activity, acting on peroxide as acceptor",GO:0016684,Parkinson Disease,MESH:D010300,0,,1,PARK7
"oxidoreductase activity, acting on peroxide as acceptor",GO:0016684,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
"oxidoreductase activity, acting on peroxide as acceptor",GO:0016684,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
"oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor",GO:0016620,Parkinson Disease,MESH:D010300,0,,1,ALDH2
"oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor",GO:0016620,Parkinsonian Disorders,MESH:D020734,0,,3,ALDH1A1|ALDH1A2|GAPDH
"oxidoreductase activity, acting on the CH-CH group of donors",GO:0016627,Parkinson Disease,MESH:D010300,0,,1,ALDH2
"oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor",GO:0016616,Parkinson Disease,MESH:D010300,0,,1,GPDH1
oxoglutarate dehydrogenase (succinyl-transferring) activity,GO:0004591,Parkinson Disease,MESH:D010300,1,Selegiline,0,
oxoglutarate dehydrogenase (succinyl-transferring) activity,GO:0004591,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
oxoglutarate dehydrogenase (succinyl-transferring) activity,GO:0004591,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Selegiline,0,
oxygen binding,GO:0019825,Parkinson Disease,MESH:D010300,1,Atrazine,4,CYP2E1|HBG1|SOD2|TH
oxygen binding,GO:0019825,"Parkinson Disease, Secondary",MESH:D010302,3,Atrazine|Benzo(a)pyrene|Resveratrol,0,
oxygen binding,GO:0019825,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Resveratrol,1,TH
oxygen carrier activity,GO:0005344,Parkinson Disease,MESH:D010300,0,,1,HBG1
oxygen sensor activity,GO:0019826,Parkinson Disease,MESH:D010300,0,,1,PARK7
oxygen sensor activity,GO:0019826,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
oxygen sensor activity,GO:0019826,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
patched binding,GO:0005113,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
PDZ domain binding,GO:0030165,Parkinson Disease,MESH:D010300,0,,3,CNTNAP2|KCNJ4|PRKN
PDZ domain binding,GO:0030165,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
PDZ domain binding,GO:0030165,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
pentosyltransferase activity,GO:0016763,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
peptidase activator activity,GO:0016504,Parkinson Disease,MESH:D010300,0,,1,PINK1
peptidase activator activity,GO:0016504,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
peptidase activator activity,GO:0016504,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
peptidase activator activity involved in apoptotic process,GO:0016505,Parkinson Disease,MESH:D010300,5,1-Methyl-4-phenylpyridinium|Eicosapentaenoic Acid|Melatonin|Oxidopamine|Rotenone,0,
peptidase activator activity involved in apoptotic process,GO:0016505,"Parkinson Disease, Secondary",MESH:D010302,6,3-methyladenine|Doxorubicin|Melatonin|Oxidopamine|Rotenone|Valproic Acid,0,
peptidase activator activity involved in apoptotic process,GO:0016505,Parkinsonian Disorders,MESH:D020734,7,1-Methyl-4-phenylpyridinium|Docosahexaenoic Acids|Melatonin|Oxidopamine|Plant Extracts|Rotenone|Valproic Acid,0,
peptidase activity,GO:0008233,Parkinson Disease,MESH:D010300,3,Dopamine|Particulate Matter|Vehicle Emissions,1,PARK7
peptidase activity,GO:0008233,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
peptidase activity,GO:0008233,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
peptidase activity,GO:0008233,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
peptidase activity,GO:0008233,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
peptidase activity,GO:0008233,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
peptidase activity,GO:0008233,Parkinsonian Disorders,MESH:D020734,2,Dopamine|Particulate Matter,2,HTRA2|PARK7
peptidase inhibitor activity,GO:0030414,Parkinson Disease,MESH:D010300,0,,2,NGF|PARK7
peptidase inhibitor activity,GO:0030414,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
peptidase inhibitor activity,GO:0030414,Parkinsonian Disorders,MESH:D020734,0,,2,NGF|PARK7
peptide antigen binding,GO:0042605,Parkinson Disease,MESH:D010300,0,,3,HFE|HLA-DRA|HLA-DRB5
peptidyl-cysteine S-nitrosylase activity,GO:0035605,Parkinson Disease,MESH:D010300,0,,1,NOS1
peptidyl-cysteine S-nitrosylase activity,GO:0035605,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
peroxidase activity,GO:0004601,Parkinson Disease,MESH:D010300,2,Atrazine|Carbon Tetrachloride,1,HBG1
peroxidase activity,GO:0004601,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
peroxidase activity,GO:0004601,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
peroxidase inhibitor activity,GO:0036479,Parkinson Disease,MESH:D010300,0,,1,LRRK2
peroxidase inhibitor activity,GO:0036479,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
peroxidase inhibitor activity,GO:0036479,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
peroxiredoxin activity,GO:0051920,Parkinson Disease,MESH:D010300,0,,1,PARK7
peroxiredoxin activity,GO:0051920,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
peroxiredoxin activity,GO:0051920,Parkinsonian Disorders,MESH:D020734,0,,2,DJ-1BETA|PARK7
peroxisome proliferator activated receptor binding,GO:0042975,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
phenylacetaldehyde dehydrogenase activity,GO:0008957,Parkinson Disease,MESH:D010300,0,,1,ALDH2
phosphatase activity,GO:0016791,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
phosphatase activity,GO:0016791,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
phosphatase activity,GO:0016791,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
phosphatidic acid binding,GO:0070300,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
phosphatidic acid binding,GO:0070300,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
phosphatidic acid binding,GO:0070300,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
phosphatidylcholine floppase activity,GO:0090554,Parkinson Disease,MESH:D010300,0,,1,ABCB1
phosphatidylcholine floppase activity,GO:0090554,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
phosphatidylethanolamine flippase activity,GO:0090555,Parkinson Disease,MESH:D010300,0,,1,ABCB1
phosphatidylethanolamine flippase activity,GO:0090555,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
"phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity",GO:0016314,Parkinson Disease,MESH:D010300,0,,1,GAK
"phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity",GO:0016314,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
"phosphatidylinositol-3,5-bisphosphate 3-phosphatase activity",GO:0052629,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
"phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity",GO:0043813,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
"phosphatidylinositol-3,5-bisphosphate binding",GO:0080025,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
"phosphatidylinositol-3,5-bisphosphate binding",GO:0080025,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
"phosphatidylinositol-3,5-bisphosphate binding",GO:0080025,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
phosphatidylinositol 3-kinase binding,GO:0043548,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
phosphatidylinositol-3-phosphate phosphatase activity,GO:0004438,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
"phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity",GO:0004439,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
phosphatidylinositol-4-phosphate phosphatase activity,GO:0043812,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
phosphatidylinositol binding,GO:0035091,Parkinson Disease,MESH:D010300,0,,1,MAPT
phosphatidylinositol binding,GO:0035091,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
phosphatidylinositol binding,GO:0035091,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
phosphatidylinositol bisphosphate binding,GO:1902936,Parkinson Disease,MESH:D010300,0,,1,MAPT
phosphatidylinositol bisphosphate binding,GO:1902936,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
phosphatidylinositol bisphosphate binding,GO:1902936,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
phosphatidylinositol phosphate 4-phosphatase activity,GO:0034596,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
phosphatidylinositol phosphate 5-phosphatase activity,GO:0034595,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
phosphatidylinositol phosphate phosphatase activity,GO:0052866,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
phosphatidylserine floppase activity,GO:0090556,Parkinson Disease,MESH:D010300,1,Reactive Oxygen Species,0,
phosphoenolpyruvate carboxykinase activity,GO:0004611,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
phosphofructokinase activity,GO:0008443,Parkinson Disease,MESH:D010300,1,Acrolein,0,
phospholipase A2 activity,GO:0004623,Parkinson Disease,MESH:D010300,1,Eicosapentaenoic Acid,0,
phospholipase A2 activity,GO:0004623,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
phospholipase A2 activity,GO:0004623,"Parkinson Disease, Secondary",MESH:D010302,1,thymoquinone,0,
phospholipase A2 activity,GO:0004623,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Docosahexaenoic Acids|Indomethacin,0,
phospholipase binding,GO:0043274,Parkinson Disease,MESH:D010300,0,,2,PRKN|SNCA
phospholipase binding,GO:0043274,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
phospholipase binding,GO:0043274,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
phospholipase binding,GO:0043274,"Parkinson Disease, Secondary",MESH:D010302,0,,2,PRKN|SNCA
phospholipase binding,GO:0043274,Parkinsonian Disorders,MESH:D020734,0,,2,PRKN|SNCA
phospholipase D activity,GO:0004630,Parkinson Disease,MESH:D010300,1,Oxidopamine,1,HMOX1
phospholipase D activity,GO:0004630,"Parkinson Disease, Secondary",MESH:D010302,1,Oxidopamine,0,
phospholipase D activity,GO:0004630,Parkinsonian Disorders,MESH:D020734,1,Oxidopamine,0,
phospholipid binding,GO:0005543,Parkinson Disease,MESH:D010300,0,,4,DEFA4|KST|RTNL1|SNCA
phospholipid binding,GO:0005543,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
phospholipid binding,GO:0005543,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
phospholipid binding,GO:0005543,"Parkinson Disease, Secondary",MESH:D010302,0,,2,PON1|SNCA
phospholipid binding,GO:0005543,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
phospholipid-hydroperoxide glutathione peroxidase activity,GO:0047066,Parkinson Disease,MESH:D010300,0,,1,CP
phosphoprotein binding,GO:0051219,Parkinson Disease,MESH:D010300,0,,3,IGF2R|NOS1|SNCA
phosphoprotein binding,GO:0051219,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
phosphoprotein binding,GO:0051219,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
phosphoprotein binding,GO:0051219,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
phosphoprotein binding,GO:0051219,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
phosphoprotein phosphatase activity,GO:0004721,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
phosphoprotein phosphatase activity,GO:0004721,Parkinson Disease,MESH:D010300,1,beta-N-methylamino-L-alanine,0,
phosphoprotein phosphatase activity,GO:0004721,Parkinsonian Disorders,MESH:D020734,1,6-methyl-2-(phenylethynyl)pyridine,0,
phosphopyruvate hydratase activity,GO:0004634,Parkinson Disease,MESH:D010300,0,,1,ENO2
phosphorus-oxygen lyase activity,GO:0016849,Parkinson Disease,MESH:D010300,0,,1,BST1
phosphorylase kinase regulator activity,GO:0008607,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
placental growth factor receptor activity,GO:0036332,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
platelet-derived growth factor alpha-receptor activity,GO:0005018,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
platelet-derived growth factor beta-receptor activity,GO:0005019,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
polyamine transmembrane transporter activity,GO:0015203,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
polyamine transmembrane transporter activity,GO:0015203,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
polyamine transmembrane transporter activity,GO:0015203,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
polysaccharide binding,GO:0030247,Parkinson Disease,MESH:D010300,0,,1,HLA-DRA
polyubiquitin modification-dependent protein binding,GO:0031593,Parkinson Disease,MESH:D010300,0,,1,PRKN
polyubiquitin modification-dependent protein binding,GO:0031593,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
polyubiquitin modification-dependent protein binding,GO:0031593,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
pore-forming activity,GO:0140911,Parkinson Disease,MESH:D010300,0,,1,DEFA4
porphobilinogen synthase activity,GO:0004655,Parkinson Disease,MESH:D010300,0,,1,HSC70-3
potassium channel regulator activity,GO:0015459,Parkinson Disease,MESH:D010300,0,,1,DRD2
potassium channel regulator activity,GO:0015459,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
pre-miRNA binding,GO:0070883,Parkinsonian Disorders,MESH:D020734,0,,1,PRKRA
primary amine oxidase activity,GO:0008131,Parkinson Disease,MESH:D010300,0,,2,MAOA|MAOB
prolactin receptor binding,GO:0005148,Parkinsonian Disorders,MESH:D020734,0,,1,PRL
proline-rich region binding,GO:0070064,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
proline:sodium symporter activity,GO:0005298,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
promoter-specific chromatin binding,GO:1990841,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
prostaglandin-endoperoxide synthase activity,GO:0004666,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
prostaglandin-endoperoxide synthase activity,GO:0004666,"Parkinson Disease, Secondary",MESH:D010302,1,thymoquinone,0,
prostaglandin-endoperoxide synthase activity,GO:0004666,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
protease binding,GO:0002020,Parkinson Disease,MESH:D010300,0,,7,CNTNAP2|FCER2|HSPA1A|INS|PINK1|SLC6A3|TNF
protease binding,GO:0002020,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
protease binding,GO:0002020,Parkinsonian Disorders,MESH:D020734,0,,2,PINK1|POLG
protease binding,GO:0002020,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
protein-arginine deiminase activity,GO:0004668,Parkinson Disease,MESH:D010300,1,Dieldrin,0,
protein-arginine deiminase activity,GO:0004668,"Parkinson Disease, Secondary",MESH:D010302,1,Dieldrin,0,
protein binding,GO:0005515,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
protein binding,GO:0005515,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
protein binding,GO:0005515,Parkinson Disease,MESH:D010300,1,Lead,81,ABCB1|AIF1|ALDH2|ATP13A2|BAG5|BDNF|CEACAM6|CHP|CNTNAP2|CPR|DDC|DDIT4|DNM1L|DRAXIN|DRD1|DRD2|EDN1|ENO2|FBP1|FCER2|FGB|GAK|GBA1|GDNF|GFAP|GSTA4|GSTM1|GSTP1|HFE|HGF|HLA-DRA|HLA-DRB5|HMOX1|HSC70-3|HSPA1A|HSPA9|IGF1R|IGF2|IGF2R|IL6|INS|INSR|KCNJ4|KST|LRRK2|MAG|MAOA|MAOB|MAP2|MAP3K5|MAPT|MTA1|MTHFR|NCAPG2|NECTIN2|NGF|NOS1|NQO1|PARK7|PINK1|PPARGC1A|PRKN|RAB32|RDGA|RPL14|RPL23A|RPL6|RPS8|SLC18A2|SLC30A10|SLC38A2|SLC6A3|SNCA|SOD1|SOD2|TALDO1|TCL1B|TH|TMEM230|TNF|VPS35
protein binding,GO:0005515,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
protein binding,GO:0005515,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
protein binding,GO:0005515,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
protein binding,GO:0005515,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
protein binding,GO:0005515,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
protein binding,GO:0005515,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
protein binding,GO:0005515,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
protein binding,GO:0005515,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
protein binding,GO:0005515,"PARKINSON DISEASE 22, AUTOSOMAL DOMINANT",OMIM:616710,0,,1,CHCHD2
protein binding,GO:0005515,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
protein binding,GO:0005515,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
protein binding,GO:0005515,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
protein binding,GO:0005515,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
protein binding,GO:0005515,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
protein binding,GO:0005515,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,8,ADH1C|ATXN2|ATXN3|GBA1|MAPT|NR4A2|SNCAIP|TBP
protein binding,GO:0005515,"Parkinson Disease, Mitochondrial",MESH:C564015,0,,1,FMC1
protein binding,GO:0005515,"Parkinson Disease, Secondary",MESH:D010302,0,,13,ABCB1|ATP13A2|BCHE|CNR2|FMC1|GDNF|NOS2|PRKN|RGS2|SHH|SLC18A2|SNCA|TFAM
protein binding,GO:0005515,Parkinsonian Disorders,MESH:D020734,0,,28,ALDH1A1|ATP13A2|ATP1A3|DCTN1|DDC|DRD2|GAPDH|GBA1|GDNF|HOTAIR|HTRA2|LRRK2|MAPT|NGF|PARK7|PARP1|PDYN|PINK1|PNOC|POLG|PRKCD|PRKN|PRKRA|PRL|SLC18A2|SLC30A10|SNCA|TH
protein binding,GO:0005515,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
protein binding,GO:0005515,"Parkinsonism, early onset with mental retardation",MESH:C537179,0,,1,RAB39B
protein binding,GO:0005515,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
protein binding,GO:0005515,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
protein-containing complex binding,GO:0044877,Parkinson Disease,MESH:D010300,0,,15,DNM1L|DRD1|DRD2|ENO2|HBG1|HGF|IGF1R|INSR|LRRK2|MAPT|MTHFR|PARK7|PINK1|PRKN|SLC6A3
protein-containing complex binding,GO:0044877,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
protein-containing complex binding,GO:0044877,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
protein-containing complex binding,GO:0044877,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
protein-containing complex binding,GO:0044877,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
protein-containing complex binding,GO:0044877,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
protein-containing complex binding,GO:0044877,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
protein-containing complex binding,GO:0044877,Parkinsonian Disorders,MESH:D020734,0,,7,DRD2|HOTAIR|LRRK2|MAPT|PARK7|PINK1|PRKN
protein-containing complex binding,GO:0044877,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
protein deglycase activity,GO:0036524,Parkinson Disease,MESH:D010300,0,,1,PARK7
protein deglycase activity,GO:0036524,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
protein deglycase activity,GO:0036524,Parkinsonian Disorders,MESH:D020734,0,,2,DJ-1BETA|PARK7
protein dimerization activity,GO:0046983,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
protein disulfide isomerase activity,GO:0003756,Parkinson Disease,MESH:D010300,1,Methamphetamine,0,
protein disulfide isomerase activity,GO:0003756,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
protein domain specific binding,GO:0019904,Parkinson Disease,MESH:D010300,0,,5,DDC|INSR|MAP3K5|SNCA|TH
protein domain specific binding,GO:0019904,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
protein domain specific binding,GO:0019904,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
protein domain specific binding,GO:0019904,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
protein domain specific binding,GO:0019904,Parkinsonian Disorders,MESH:D020734,0,,3,DDC|SNCA|TH
protein folding chaperone,GO:0044183,Parkinson Disease,MESH:D010300,0,,1,HSPA1A
protein-glutamine gamma-glutamyltransferase activity,GO:0003810,"Parkinson Disease, Secondary",MESH:D010302,4,Doxorubicin|Silymarin|thymoquinone|Valproic Acid,0,
protein-glutamine gamma-glutamyltransferase activity,GO:0003810,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Silymarin|Valproic Acid,0,
protein heterodimerization activity,GO:0046982,Parkinson Disease,MESH:D010300,0,,1,CEACAM6
protein heterodimerization activity,GO:0046982,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
protein homodimerization activity,GO:0042803,Parkinson Disease,MESH:D010300,0,,13,DEFA4|DNM1L|GDNF|GPDH1|GSTA4|GSTM1|HMOX1|LRRK2|MAG|MAP3K5|NECTIN2|PARK7|SOD1
protein homodimerization activity,GO:0042803,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
protein homodimerization activity,GO:0042803,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
protein homodimerization activity,GO:0042803,"Parkinson Disease, Secondary",MESH:D010302,0,,3,GDNF|NOS2|PON1
protein homodimerization activity,GO:0042803,Parkinsonian Disorders,MESH:D020734,0,,5,GDNF|LRRK2|PARK7|PARP1|PRKRA
protein kinase A binding,GO:0051018,Parkinson Disease,MESH:D010300,0,,1,LRRK2
protein kinase A binding,GO:0051018,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
protein kinase A binding,GO:0051018,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
protein kinase activator activity,GO:0030295,Parkinson Disease,MESH:D010300,0,,1,INSR
protein kinase activator activity,GO:0030295,Parkinsonian Disorders,MESH:D020734,0,,1,PRKRA
protein kinase activator activity,GO:0030295,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
protein kinase activity,GO:0004672,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
protein kinase activity,GO:0004672,Parkinson Disease,MESH:D010300,0,,5,GAK|INSR|LRRK2|MAP3K5|PINK1
protein kinase activity,GO:0004672,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
protein kinase activity,GO:0004672,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
protein kinase activity,GO:0004672,Parkinsonian Disorders,MESH:D020734,0,,3,LRRK2|PINK1|PRKCD
protein kinase B binding,GO:0043422,Parkinson Disease,MESH:D010300,0,,1,PINK1
protein kinase B binding,GO:0043422,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
protein kinase B binding,GO:0043422,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
protein kinase binding,GO:0019901,Parkinson Disease,MESH:D010300,0,,10,BAG5|GSTM1|GSTP1|INSR|MAG|MAP2|MAP3K5|MAPT|PRKN|TCL1B
protein kinase binding,GO:0019901,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
protein kinase binding,GO:0019901,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
protein kinase binding,GO:0019901,"Parkinson Disease, Secondary",MESH:D010302,0,,2,NOS2|PRKN
protein kinase binding,GO:0019901,Parkinsonian Disorders,MESH:D020734,0,,6,DCTN1|MAPT|PARP1|PRKCD|PRKN|PRKRA
protein kinase binding,GO:0019901,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
protein kinase C activity,GO:0004697,Parkinson Disease,MESH:D010300,5,Endosulfan|Hexachlorocyclohexane|Lead|Paraquat|Trichloroethylene,0,
protein kinase C activity,GO:0004697,"Parkinson Disease, Secondary",MESH:D010302,3,Paraquat|Silymarin|Trichloroethylene,0,
protein kinase C activity,GO:0004697,Parkinsonian Disorders,MESH:D020734,2,Paraquat|Silymarin,1,PRKCD
protein kinase inhibitor activity,GO:0004860,Parkinson Disease,MESH:D010300,0,,1,SNCA
protein kinase inhibitor activity,GO:0004860,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
protein kinase inhibitor activity,GO:0004860,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
protein kinase inhibitor activity,GO:0004860,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
protein kinase inhibitor activity,GO:0004860,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
protein kinase regulator activity,GO:0019887,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
protein lysine deacetylase activity,GO:0033558,Parkinson Disease,MESH:D010300,1,Paraquat,0,
protein lysine deacetylase activity,GO:0033558,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
protein lysine deacetylase activity,GO:0033558,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
protein-macromolecule adaptor activity,GO:0030674,Parkinson Disease,MESH:D010300,0,,2,COL19A1|MAPT
protein-macromolecule adaptor activity,GO:0030674,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
protein-macromolecule adaptor activity,GO:0030674,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
protein phosphatase 2A binding,GO:0051721,Parkinson Disease,MESH:D010300,0,,2,MAPT|SLC6A3
protein phosphatase 2A binding,GO:0051721,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
protein phosphatase 2A binding,GO:0051721,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
protein phosphatase 2A binding,GO:0051721,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
protein phosphatase 2B binding,GO:0030346,Parkinson Disease,MESH:D010300,0,,1,SOD1
protein phosphatase binding,GO:0019903,Parkinson Disease,MESH:D010300,0,,3,DRD1|INSR|MAP3K5
protein serine kinase activity,GO:0106310,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
protein serine kinase activity,GO:0106310,Parkinson Disease,MESH:D010300,0,,4,GAK|LRRK2|MAP3K5|PINK1
protein serine kinase activity,GO:0106310,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
protein serine kinase activity,GO:0106310,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
protein serine kinase activity,GO:0106310,Parkinsonian Disorders,MESH:D020734,0,,3,LRRK2|PINK1|PRKCD
protein serine/threonine kinase activator activity,GO:0043539,Parkinson Disease,MESH:D010300,0,,2,IGF2|TCL1B
protein serine/threonine kinase activity,GO:0004674,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
protein serine/threonine kinase activity,GO:0004674,Parkinson Disease,MESH:D010300,0,,4,GAK|LRRK2|MAP3K5|PINK1
protein serine/threonine kinase activity,GO:0004674,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
protein serine/threonine kinase activity,GO:0004674,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
protein serine/threonine kinase activity,GO:0004674,Parkinsonian Disorders,MESH:D020734,0,,3,LRRK2|PINK1|PRKCD
protein serine/threonine kinase binding,GO:0120283,Parkinson Disease,MESH:D010300,0,,1,DNM1L
protein serine/threonine kinase binding,GO:0120283,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
protein serine/threonine kinase inhibitor activity,GO:0030291,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
protein serine/threonine kinase inhibitor activity,GO:0030291,Parkinsonian Disorders,MESH:D020734,0,,1,HTRA2
protein serine/threonine phosphatase activity,GO:0004722,Parkinson Disease,MESH:D010300,1,Estradiol,0,
protein serine/threonine phosphatase activity,GO:0004722,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,0,
protein serine/threonine phosphatase activity,GO:0004722,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
protein transporter activity,GO:0140318,Parkinson Disease,MESH:D010300,0,,1,IGF1R
protein-transporting ATPase activity,GO:0015450,Parkinson Disease,MESH:D010300,0,,1,HSC70-3
protein tyrosine kinase activity,GO:0004713,Parkinson Disease,MESH:D010300,0,,3,IGF1R|INSR|LRRK2
protein tyrosine kinase activity,GO:0004713,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
protein tyrosine kinase activity,GO:0004713,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PRKCD
protein tyrosine kinase binding,GO:1990782,Parkinson Disease,MESH:D010300,0,,1,CEACAM6
protein tyrosine kinase collagen receptor activity,GO:0038062,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
protein tyrosine phosphatase activity,GO:0004725,Parkinson Disease,MESH:D010300,2,Particulate Matter|Vehicle Emissions,0,
protein tyrosine phosphatase activity,GO:0004725,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
protein tyrosine phosphatase activity,GO:0004725,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
"protein tyrosine phosphatase activity, metal-dependent",GO:0030946,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
"proton-transporting ATPase activity, rotational mechanism",GO:0046961,Parkinson Disease,MESH:D010300,2,Dicamba|Zinc,0,
"proton-transporting ATPase activity, rotational mechanism",GO:0046961,"Parkinson Disease, Secondary",MESH:D010302,2,Chlorpromazine|Resveratrol,0,
"proton-transporting ATPase activity, rotational mechanism",GO:0046961,Parkinsonian Disorders,MESH:D020734,4,Chlorpromazine|coenzyme Q10|Curcumin|Resveratrol,0,
"proton-transporting ATP synthase activity, rotational mechanism",GO:0046933,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,1,ATPSYNBETA
"proton-transporting ATP synthase activity, rotational mechanism",GO:0046933,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
PTB domain binding,GO:0051425,Parkinson Disease,MESH:D010300,0,,1,INSR
P-type calcium transporter activity,GO:0005388,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Rotenone,0,
P-type calcium transporter activity,GO:0005388,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
P-type calcium transporter activity,GO:0005388,Parkinsonian Disorders,MESH:D020734,5,Cadmium|Curcumin|Docosahexaenoic Acids|Lipopolysaccharides|Rotenone,0,
P-type ion transporter activity,GO:0015662,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
P-type ion transporter activity,GO:0015662,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
P-type ion transporter activity,GO:0015662,Parkinsonian Disorders,MESH:D020734,1,Phenol,1,ATP13A2
P-type magnesium transporter activity,GO:0015444,Parkinson Disease,MESH:D010300,1,Atrazine,0,
P-type magnesium transporter activity,GO:0015444,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
P-type magnesium transporter activity,GO:0015444,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
P-type potassium transmembrane transporter activity,GO:0008556,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
P-type sodium:potassium-exchanging transporter activity,GO:0005391,Parkinson Disease,MESH:D010300,11,1-Methyl-4-phenylpyridinium|Chlorpyrifos|Dopamine|Lead|Levodopa|Lipopolysaccharides|Lithium Carbonate|Manganese|Reserpine|Rotenone|Zinc,0,
P-type sodium:potassium-exchanging transporter activity,GO:0005391,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
P-type sodium:potassium-exchanging transporter activity,GO:0005391,"Parkinson Disease, Secondary",MESH:D010302,8,Chlorpromazine|Levodopa|Lithium Carbonate|Manganese|Reserpine|Resveratrol|Rotenone|Valproic Acid,0,
P-type sodium:potassium-exchanging transporter activity,GO:0005391,Parkinsonian Disorders,MESH:D020734,17,1-Methyl-4-phenylpyridinium|Cadmium|Chlorpromazine|coenzyme Q10|Curcumin|Docosahexaenoic Acids|Dopamine|Indomethacin|Levodopa|Lipopolysaccharides|Manganese|manganese chloride|Reserpine|Resveratrol|Rotenone|taxifolin|Valproic Acid,1,ATP1A3
P-type sodium:potassium-exchanging transporter activity,GO:0005391,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
P-type sodium:potassium-exchanging transporter activity involved in regulation of cardiac muscle cell membrane potential,GO:0086037,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
P-type transmembrane transporter activity,GO:0140358,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
P-type transmembrane transporter activity,GO:0140358,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
P-type transmembrane transporter activity,GO:0140358,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
pyridoxal phosphate binding,GO:0030170,Parkinson Disease,MESH:D010300,0,,1,DDC
pyridoxal phosphate binding,GO:0030170,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
pyruvate dehydrogenase activity,GO:0004738,Parkinson Disease,MESH:D010300,1,Selegiline,0,
pyruvate dehydrogenase activity,GO:0004738,Parkinsonian Disorders,MESH:D020734,1,Selegiline,0,
pyruvate kinase activity,GO:0004743,Parkinson Disease,MESH:D010300,4,Air Pollutants|Lead|Lithium Carbonate|Particulate Matter,0,
pyruvate kinase activity,GO:0004743,"Parkinson Disease, Secondary",MESH:D010302,1,Lithium Carbonate,0,
pyruvate kinase activity,GO:0004743,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
receptor ligand activity,GO:0048018,Parkinson Disease,MESH:D010300,0,,6,EDN1|GDNF|HSPA1A|IGF2|NECTIN2|TNF
receptor ligand activity,GO:0048018,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
receptor ligand activity,GO:0048018,Parkinsonian Disorders,MESH:D020734,0,,2,GDNF|PNOC
receptor serine/threonine kinase binding,GO:0033612,Parkinson Disease,MESH:D010300,0,,1,LRRK2
receptor serine/threonine kinase binding,GO:0033612,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
receptor serine/threonine kinase binding,GO:0033612,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
receptor tyrosine kinase binding,GO:0030971,Parkinson Disease,MESH:D010300,0,,1,GDNF
receptor tyrosine kinase binding,GO:0030971,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
receptor tyrosine kinase binding,GO:0030971,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
retinal binding,GO:0016918,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
retinal dehydrogenase activity,GO:0001758,Parkinsonian Disorders,MESH:D020734,0,,2,ALDH1A1|ALDH1A2
retinoic acid binding,GO:0001972,Parkinson Disease,MESH:D010300,0,,1,IGF2R
retromer complex binding,GO:1905394,Parkinson Disease,MESH:D010300,0,,1,IGF2R
Rho-dependent protein serine/threonine kinase activity,GO:0072518,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
Rho-dependent protein serine/threonine kinase activity,GO:0072518,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
Rho-dependent protein serine/threonine kinase activity,GO:0072518,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
Rho-dependent protein serine/threonine kinase activity,GO:0072518,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
Rho-dependent protein serine/threonine kinase activity,GO:0072518,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
ribosomal protein S6 kinase activity,GO:0004711,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
ribosomal protein S6 kinase activity,GO:0004711,Parkinson Disease,MESH:D010300,0,,3,GAK|LRRK2|PINK1
ribosomal protein S6 kinase activity,GO:0004711,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
ribosomal protein S6 kinase activity,GO:0004711,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
ribosomal protein S6 kinase activity,GO:0004711,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|PINK1
ribosome binding,GO:0043022,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
RNA 7-methylguanosine cap binding,GO:0000340,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
RNA binding,GO:0003723,Parkinson Disease,MESH:D010300,0,,7,ADARB2|MAPT|PARK7|PPARGC1A|RPL14|RPL23A|RPL6
RNA binding,GO:0003723,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
RNA binding,GO:0003723,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
RNA binding,GO:0003723,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
RNA binding,GO:0003723,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,ATXN2|MAPT
RNA binding,GO:0003723,Parkinsonian Disorders,MESH:D020734,0,,3,MAPT|PARK7|PRKRA
RNA-dependent RNA polymerase activity,GO:0003968,Parkinson Disease,MESH:D010300,0,,1,NCAPG2
RNA polymerase binding,GO:0070063,Parkinson Disease,MESH:D010300,1,Estradiol,0,
RNA polymerase I core promoter sequence-specific DNA binding,GO:0001164,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
RNA polymerase II cis-regulatory region sequence-specific DNA binding,GO:0000978,Parkinson Disease,MESH:D010300,0,,1,MTA1
RNA polymerase II cis-regulatory region sequence-specific DNA binding,GO:0000978,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,NR4A2|TBP
RNA polymerase II core promoter sequence-specific DNA binding,GO:0000979,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
RNA polymerase II general transcription initiation factor activity,GO:0016251,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
RNA polymerase II general transcription initiation factor binding,GO:0001091,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
RNA polymerase III general transcription initiation factor activity,GO:0000995,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
RNA polymerase III type 3 promoter sequence-specific DNA binding,GO:0001006,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
RNA polymerase II-specific DNA-binding transcription factor binding,GO:0061629,Parkinson Disease,MESH:D010300,0,,4,FBP1|MTA1|NOS1|PPARGC1A
RNA polymerase II-specific DNA-binding transcription factor binding,GO:0061629,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
RNA polymerase II-specific DNA-binding transcription factor binding,GO:0061629,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
RNA polymerase II transcription regulatory region sequence-specific DNA binding,GO:0000977,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,ATXN3|NR4A2
rRNA binding,GO:0019843,Parkinson Disease,MESH:D010300,0,,1,RPL23A
R-SMAD binding,GO:0070412,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
scaffold protein binding,GO:0097110,Parkinson Disease,MESH:D010300,0,,2,NOS1|PARK7
scaffold protein binding,GO:0097110,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
scaffold protein binding,GO:0097110,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
scavenger receptor binding,GO:0005124,Parkinson Disease,MESH:D010300,0,,1,GBA1
scavenger receptor binding,GO:0005124,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
scavenger receptor binding,GO:0005124,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
sequence-specific DNA binding,GO:0043565,Parkinson Disease,MESH:D010300,0,,3,MAPT|MTA1|PPARGC1A
sequence-specific DNA binding,GO:0043565,"PARKINSON DISEASE 22, AUTOSOMAL DOMINANT",OMIM:616710,0,,1,CHCHD2
sequence-specific DNA binding,GO:0043565,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,MAPT|NR4A2
sequence-specific DNA binding,GO:0043565,"Parkinson Disease, Secondary",MESH:D010302,0,,1,TFAM
sequence-specific DNA binding,GO:0043565,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
sequence-specific double-stranded DNA binding,GO:1990837,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
serine hydrolase activity,GO:0017171,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
serine-type endopeptidase activity,GO:0004252,Parkinson Disease,MESH:D010300,0,,1,HGF
serine-type endopeptidase activity,GO:0004252,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
serine-type endopeptidase activity,GO:0004252,Parkinsonian Disorders,MESH:D020734,0,,1,HTRA2
serine-type peptidase activity,GO:0008236,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
serine-type peptidase activity,GO:0008236,Parkinsonian Disorders,MESH:D020734,0,,1,HTRA2
serotonin binding,GO:0051378,Parkinson Disease,MESH:D010300,0,,1,MAOA
serotonin:sodium:chloride symporter activity,GO:0005335,Parkinson Disease,MESH:D010300,0,,1,SLC18A2
serotonin:sodium:chloride symporter activity,GO:0005335,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SLC18A2
serotonin:sodium:chloride symporter activity,GO:0005335,Parkinsonian Disorders,MESH:D020734,0,,1,SLC18A2
SH2 domain binding,GO:0042169,Parkinson Disease,MESH:D010300,0,,1,MAP2
SH3 domain binding,GO:0017124,Parkinson Disease,MESH:D010300,0,,2,MAPT|PRKN
SH3 domain binding,GO:0017124,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
SH3 domain binding,GO:0017124,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
SH3 domain binding,GO:0017124,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
SH3 domain binding,GO:0017124,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
SH3 domain binding,GO:0017124,Parkinsonian Disorders,MESH:D020734,0,,2,MAPT|PRKN
sialic acid binding,GO:0033691,Parkinson Disease,MESH:D010300,0,,1,MAG
signaling receptor activator activity,GO:0030546,Parkinson Disease,MESH:D010300,0,,1,PARK7
signaling receptor activator activity,GO:0030546,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
signaling receptor activator activity,GO:0030546,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
signaling receptor activity,GO:0038023,Parkinson Disease,MESH:D010300,0,,3,CP|FCER2|IGF2R
signaling receptor activity,GO:0038023,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
signaling receptor binding,GO:0005102,Parkinson Disease,MESH:D010300,0,,16,BDNF|DRD1|DRD2|EDN1|FGB|GBA1|GDNF|HFE|HGF|HSPA1A|IL6|LRRK2|MAG|NGF|PARK7|SLC6A3
signaling receptor binding,GO:0005102,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
signaling receptor binding,GO:0005102,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
signaling receptor binding,GO:0005102,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
signaling receptor binding,GO:0005102,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
signaling receptor binding,GO:0005102,Parkinsonian Disorders,MESH:D020734,0,,6,DRD2|GBA1|GDNF|LRRK2|NGF|PARK7
signaling receptor binding,GO:0005102,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
signaling receptor complex adaptor activity,GO:0030159,Parkinson Disease,MESH:D010300,0,,1,LRRK2
signaling receptor complex adaptor activity,GO:0030159,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
signaling receptor complex adaptor activity,GO:0030159,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
single-stranded DNA 3'-5' exodeoxyribonuclease activity,GO:0008310,Parkinsonian Disorders,MESH:D020734,0,,1,POLG
single-stranded DNA binding,GO:0003697,Parkinson Disease,MESH:D010300,0,,1,MAPT
single-stranded DNA binding,GO:0003697,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
single-stranded DNA binding,GO:0003697,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
single-stranded RNA binding,GO:0003727,Parkinson Disease,MESH:D010300,0,,2,ADARB2|MIR181C
siRNA binding,GO:0035197,Parkinsonian Disorders,MESH:D020734,0,,1,PRKRA
small GTPase binding,GO:0031267,Parkinson Disease,MESH:D010300,0,,4,DNM1L|LRRK2|SOD1|VPS35
small GTPase binding,GO:0031267,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
small GTPase binding,GO:0031267,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
small GTPase binding,GO:0031267,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
small molecule binding,GO:0036094,Parkinson Disease,MESH:D010300,0,,1,TH
small molecule binding,GO:0036094,Parkinsonian Disorders,MESH:D020734,0,,1,TH
small protein activating enzyme binding,GO:0044388,Parkinson Disease,MESH:D010300,0,,1,PARK7
small protein activating enzyme binding,GO:0044388,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
small protein activating enzyme binding,GO:0044388,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
SNARE binding,GO:0000149,Parkinson Disease,MESH:D010300,0,,2,LRRK2|SNCA
SNARE binding,GO:0000149,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
SNARE binding,GO:0000149,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
SNARE binding,GO:0000149,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
SNARE binding,GO:0000149,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
SNARE binding,GO:0000149,Parkinsonian Disorders,MESH:D020734,0,,2,LRRK2|SNCA
S-nitrosoglutathione binding,GO:0035730,Parkinson Disease,MESH:D010300,0,,1,GSTP1
snoRNA binding,GO:0030515,Parkinsonian Disorders,MESH:D020734,0,,1,DCTN1
sodium channel activity,GO:0005272,Parkinson Disease,MESH:D010300,0,,1,TRPM2
sodium channel activity,GO:0005272,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
sodium channel activity,GO:0005272,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Resveratrol,0,
sodium channel regulator activity,GO:0017080,Parkinson Disease,MESH:D010300,0,,1,NOS1
solute:bicarbonate symporter activity,GO:0140410,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
starch synthase activity,GO:0009011,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
stem cell factor receptor activity,GO:0005020,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
steroid binding,GO:0005496,Parkinson Disease,MESH:D010300,0,,1,GSTM1
steroid delta-isomerase activity,GO:0004769,Parkinson Disease,MESH:D010300,1,Eicosapentaenoic Acid,0,
steroid delta-isomerase activity,GO:0004769,Parkinsonian Disorders,MESH:D020734,1,Docosahexaenoic Acids,0,
steroid hormone binding,GO:1990239,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
steroid sulfotransferase activity,GO:0050294,Parkinson Disease,MESH:D010300,1,Estradiol,0,
sterol esterase activity,GO:0004771,Parkinson Disease,MESH:D010300,0,,1,MAG
steryl-beta-glucosidase activity,GO:0050295,Parkinson Disease,MESH:D010300,0,,1,GBA1
steryl-beta-glucosidase activity,GO:0050295,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
steryl-beta-glucosidase activity,GO:0050295,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
structural constituent of chitin-based larval cuticle,GO:0008010,Parkinson Disease,MESH:D010300,0,,2,CPR64AA|CPR66D
structural constituent of chromatin,GO:0030527,Parkinson Disease,MESH:D010300,0,,1,RPL23A
structural constituent of collagen and cuticulin-based cuticle,GO:0042329,Parkinson Disease,MESH:D010300,0,,1,COL19A1
structural constituent of cytoskeleton,GO:0005200,Parkinson Disease,MESH:D010300,0,,1,GFAP
structural constituent of eye lens,GO:0005212,Parkinson Disease,MESH:D010300,0,,2,CPR66D|RETININ
structural constituent of muscle,GO:0008307,Parkinson Disease,MESH:D010300,0,,1,MLP60A
structural constituent of ribosome,GO:0003735,Parkinson Disease,MESH:D010300,0,,7,CNTNAP2|NQO1|PINK1|RPL14|RPL23A|RPL6|RPS8
structural constituent of ribosome,GO:0003735,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
structural constituent of ribosome,GO:0003735,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
structural molecule activity,GO:0005198,Parkinson Disease,MESH:D010300,0,,6,FGB|GFAP|HMOX1|IGF1R|INSR|MAP2
succinate dehydrogenase activity,GO:0000104,Parkinson Disease,MESH:D010300,5,"carbidopa, levodopa drug combination|Lipopolysaccharides|Rotenone|Selegiline|Zinc",0,
succinate dehydrogenase activity,GO:0000104,"Parkinson Disease, Secondary",MESH:D010302,4,"carbidopa, levodopa drug combination|Doxorubicin|Rotenone|thymoquinone",0,
succinate dehydrogenase activity,GO:0000104,Parkinsonian Disorders,MESH:D020734,8,"Cadmium|carbidopa, levodopa drug combination|crocin|Curcumin|Lipopolysaccharides|Plant Extracts|Rotenone|Selegiline",0,
succinate dehydrogenase activity,GO:0000104,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
succinate dehydrogenase (ubiquinone) activity,GO:0008177,Parkinson Disease,MESH:D010300,12,"1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Aspirin|carbidopa, levodopa drug combination|Lead|Lithium|Lithium Carbonate|Melatonin|Nitrites|Paraquat|Rotenone|Sirolimus",0,
succinate dehydrogenase (ubiquinone) activity,GO:0008177,"Parkinson Disease, Secondary",MESH:D010302,8,"carbidopa, levodopa drug combination|Doxorubicin|Lithium|Lithium Carbonate|Melatonin|Paraquat|Rotenone|Valproic Acid",0,
succinate dehydrogenase (ubiquinone) activity,GO:0008177,Parkinsonian Disorders,MESH:D020734,12,"1-Methyl-4-phenylpyridinium|Bupropion|Cadmium|carbidopa, levodopa drug combination|coenzyme Q10|Curcumin|Docosahexaenoic Acids|ginsenoside Re|Melatonin|Paraquat|Rotenone|Valproic Acid",0,
succinate dehydrogenase (ubiquinone) activity,GO:0008177,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Lithium,0,
sucrose alpha-glucosidase activity,GO:0004575,Parkinson Disease,MESH:D010300,2,Lead|Paraquat,0,
sucrose alpha-glucosidase activity,GO:0004575,"Parkinson Disease, Secondary",MESH:D010302,2,geraniol|Paraquat,0,
sucrose alpha-glucosidase activity,GO:0004575,Parkinsonian Disorders,MESH:D020734,2,geraniol|Paraquat,0,
sulfotransferase activity,GO:0008146,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
superoxide dismutase activity,GO:0004784,Parkinson Disease,MESH:D010300,54,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|6,7-dihydroxyflavone|Acrolein|Air Pollutants|Aluminum|Aspirin|Atrazine|Benomyl|Carbidopa|carbidopa, levodopa drug combination|Carbon Tetrachloride|Chlorpyrifos|Copper|Diazepam|Dicamba|Ditiocarb|Endosulfan|Estradiol|Eugenol|Hexachlorocyclohexane|Homocysteine|Iron|Lead|Lipopolysaccharides|Lithium Carbonate|Manganese|mangiferin|Melatonin|Methamphetamine|Oxidopamine|Ozone|Paclitaxel|Paraquat|Particulate Matter|pendimethalin|Permethrin|Pesticides|Pioglitazone|Probenecid|Rivastigmine|Roflumilast|Rotenone|Selegiline|Sirolimus|Smoke|Soot|Tea|Testosterone|Trichloroethylene|Vehicle Emissions|Water Pollutants, Chemical|Zinc",3,NQO1|SOD1|SOD2
superoxide dismutase activity,GO:0004784,"Parkinson Disease, Secondary",MESH:D010302,41,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amiodarone|Amlodipine|Atrazine|Benzo(a)pyrene|Buspirone|Carbidopa|carbidopa, levodopa drug combination|Cimetidine|Diazepam|Dichlorvos|Ditiocarb|Doxorubicin|Exenatide|Famotidine|geraniol|Lithium Carbonate|Manganese|Melatonin|Methamphetamine|Methotrexate|Nicotine|Nifedipine|Oxidopamine|Paraquat|Paroxetine|Pesticides|PQQ Cofactor|Pyridostigmine Bromide|Resveratrol|Rotenone|Silymarin|sodium bisulfide|Tacrine|thymoquinone|Trichloroethylene|Valproic Acid|Venlafaxine Hydrochloride|Verapamil|Vincristine",0,
superoxide dismutase activity,GO:0004784,Parkinsonian Disorders,MESH:D020734,42,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Amiodarone|Amlodipine|baicalin|Buspirone|Cadmium|Carbidopa|carbidopa, levodopa drug combination|Centella asiatica extract|coenzyme Q10|crocin|Curcumin|cypermethrin|Docosahexaenoic Acids|Donepezil|genkwanin|geraniol|Indomethacin|Lipopolysaccharides|mancozeb|Manganese|manganese chloride|Melatonin|oleuropein|Oxidopamine|Paraquat|Paroxetine|Particulate Matter|Permethrin|Plant Extracts|Plant Preparations|Probenecid|Resveratrol|Rivastigmine|Rotenone|Selegiline|sesamin|Silymarin|taxifolin|Valproic Acid|Verapamil",0,
superoxide dismutase activity,GO:0004784,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
superoxide dismutase copper chaperone activity,GO:0016532,Parkinson Disease,MESH:D010300,0,,1,PARK7
superoxide dismutase copper chaperone activity,GO:0016532,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
superoxide dismutase copper chaperone activity,GO:0016532,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
superoxide-generating NADPH oxidase activity,GO:0106292,Parkinson Disease,MESH:D010300,1,Methamphetamine,0,
superoxide-generating NADPH oxidase activity,GO:0106292,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Methamphetamine,0,
superoxide-generating NADPH oxidase activity,GO:0106292,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
symporter activity,GO:0015293,Parkinson Disease,MESH:D010300,0,,2,SLC38A2|SLC6A3
symporter activity,GO:0015293,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
syntaxin-1 binding,GO:0017075,Parkinson Disease,MESH:D010300,0,,1,LRRK2
syntaxin-1 binding,GO:0017075,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
syntaxin-1 binding,GO:0017075,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
tau protein binding,GO:0048156,Parkinson Disease,MESH:D010300,0,,2,MAP2|SNCA
tau protein binding,GO:0048156,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
tau protein binding,GO:0048156,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
tau protein binding,GO:0048156,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
tau protein binding,GO:0048156,Parkinsonian Disorders,MESH:D020734,0,,2,DCTN1|SNCA
T cell receptor binding,GO:0042608,Parkinson Disease,MESH:D010300,0,,1,HLA-DRA
telomerase activity,GO:0003720,Parkinson Disease,MESH:D010300,3,Air Pollutants|Estradiol|Particulate Matter,0,
telomerase activity,GO:0003720,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
telomerase activity,GO:0003720,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
testosterone 17-beta-dehydrogenase (NADP+) activity,GO:0047045,Parkinsonian Disorders,MESH:D020734,1,mancozeb,0,
testosterone 6-beta-hydroxylase activity,GO:0050649,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
testosterone 6-beta-hydroxylase activity,GO:0050649,Parkinsonian Disorders,MESH:D020734,1,Amiodarone,0,
testosterone 6-beta-hydroxylase activity,GO:0050649,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
testosterone dehydrogenase [NAD(P)] activity,GO:0030283,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,0,
tetrahydrobiopterin binding,GO:0034617,Parkinson Disease,MESH:D010300,0,,2,NOS1|TH
tetrahydrobiopterin binding,GO:0034617,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
tetrahydrobiopterin binding,GO:0034617,Parkinsonian Disorders,MESH:D020734,0,,1,TH
TFIIA-class transcription factor complex binding,GO:0001092,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
TFIIB-class transcription factor binding,GO:0001093,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
thiolester hydrolase activity,GO:0016790,Parkinson Disease,MESH:D010300,0,,1,PARK7
thiolester hydrolase activity,GO:0016790,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
thiolester hydrolase activity,GO:0016790,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
thioredoxin-disulfide reductase activity,GO:0004791,Parkinson Disease,MESH:D010300,2,Iron|Rotenone,0,
thioredoxin-disulfide reductase activity,GO:0004791,"Parkinson Disease, Secondary",MESH:D010302,4,geraniol|Rotenone|sodium bisulfide|thymoquinone,0,
thioredoxin-disulfide reductase activity,GO:0004791,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Curcumin|geraniol|Rotenone,0,
TIR domain binding,GO:0070976,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
TORC2 complex binding,GO:1904841,Parkinson Disease,MESH:D010300,0,,2,PINK1|RPL23A
TORC2 complex binding,GO:1904841,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
TORC2 complex binding,GO:1904841,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
toxic substance binding,GO:0015643,Parkinson Disease,MESH:D010300,0,,2,GSTA4|GSTP1
transaldolase activity,GO:0004801,Parkinson Disease,MESH:D010300,0,,1,TALDO1
transaminase activity,GO:0008483,Parkinson Disease,MESH:D010300,1,"Water Pollutants, Chemical",0,
transaminase activity,GO:0008483,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
transcription cis-regulatory region binding,GO:0000976,Parkinson Disease,MESH:D010300,0,,2,SNCA|TNF
transcription cis-regulatory region binding,GO:0000976,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
transcription cis-regulatory region binding,GO:0000976,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
transcription cis-regulatory region binding,GO:0000976,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
transcription cis-regulatory region binding,GO:0000976,"Parkinson Disease, Secondary",MESH:D010302,0,,2,SNCA|TFAM
transcription cis-regulatory region binding,GO:0000976,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
transcription coactivator activity,GO:0003713,Parkinson Disease,MESH:D010300,0,,4,MAP2|MTA1|PARK7|PPARGC1A
transcription coactivator activity,GO:0003713,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
transcription coactivator activity,GO:0003713,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
transcription coactivator binding,GO:0001223,"Parkinson Disease, Secondary",MESH:D010302,0,,1,TFAM
transcription coregulator activity,GO:0003712,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
transcription coregulator activity,GO:0003712,Parkinsonian Disorders,MESH:D020734,1,Docosahexaenoic Acids,0,
transcription corepressor activity,GO:0003714,Parkinson Disease,MESH:D010300,0,,3,HSPA1A|MTA1|PRKN
transcription corepressor activity,GO:0003714,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
transcription corepressor activity,GO:0003714,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
transcription corepressor binding,GO:0001222,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
transcription factor binding,GO:0008134,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
transcription regulator activator activity,GO:0140537,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
transcription regulator inhibitor activity,GO:0140416,Parkinson Disease,MESH:D010300,0,,1,HSPA1A
transferase activity,GO:0016740,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
transferase activity,GO:0016740,Parkinson Disease,MESH:D010300,0,,10,BST1|GAK|GSTA4|GSTM1|GSTP1|LRRK2|MAP3K5|PINK1|PRKN|TALDO1
transferase activity,GO:0016740,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
transferase activity,GO:0016740,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
transferase activity,GO:0016740,"Parkinson Disease, Secondary",MESH:D010302,0,,2,PRKN|SHH
transferase activity,GO:0016740,Parkinsonian Disorders,MESH:D020734,0,,7,GAPDH|LRRK2|PARP1|PINK1|POLG|PRKN|PRKRA
transferrin receptor binding,GO:1990459,Parkinson Disease,MESH:D010300,0,,1,HFE
transforming growth factor beta binding,GO:0050431,Parkinson Disease,MESH:D010300,0,,1,CHP
transforming growth factor beta receptor binding,GO:0005160,Parkinson Disease,MESH:D010300,0,,1,GDNF
transforming growth factor beta receptor binding,GO:0005160,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
transforming growth factor beta receptor binding,GO:0005160,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
"translation factor activity, RNA binding",GO:0008135,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
translation initiation factor activity,GO:0003743,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
translation initiation factor binding,GO:0031369,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
transmembrane-ephrin receptor activity,GO:0005005,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
transmembrane receptor protein tyrosine kinase activator activity,GO:0030297,Parkinson Disease,MESH:D010300,0,,2,IGF2|NGF
transmembrane receptor protein tyrosine kinase activator activity,GO:0030297,Parkinsonian Disorders,MESH:D020734,0,,1,NGF
transmembrane receptor protein tyrosine kinase activity,GO:0004714,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
transmembrane transporter activity,GO:0022857,Parkinson Disease,MESH:D010300,0,,2,ABCB1|SLC18A2
transmembrane transporter activity,GO:0022857,"Parkinson Disease, Secondary",MESH:D010302,0,,2,ABCB1|SLC18A2
transmembrane transporter activity,GO:0022857,Parkinsonian Disorders,MESH:D020734,0,,1,SLC18A2
transmembrane transporter binding,GO:0044325,Parkinson Disease,MESH:D010300,0,,3,CNTNAP2|LRRK2|NOS1
transmembrane transporter binding,GO:0044325,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
transmembrane transporter binding,GO:0044325,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
trehalase activity,GO:0015927,Parkinson Disease,MESH:D010300,1,Ozone,0,
triglyceride lipase activity,GO:0004806,Parkinson Disease,MESH:D010300,0,,1,MAG
triplet codon-amino acid adaptor activity,GO:0030533,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TRNT
triplet codon-amino acid adaptor activity,GO:0030533,"Parkinson Disease, Mitochondrial",MESH:C564015,0,,1,TRNT
tRNA binding,GO:0000049,Parkinson Disease,MESH:D010300,0,,2,RPL6|VPS35
tRNA binding,GO:0000049,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
tRNA (cytosine-5-)-methyltransferase activity,GO:0016428,Parkinson Disease,MESH:D010300,0,,1,VPS35
tRNA (cytosine-5-)-methyltransferase activity,GO:0016428,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
tRNA-specific adenosine deaminase activity,GO:0008251,Parkinson Disease,MESH:D010300,0,,1,ADARB2
tropomyosin binding,GO:0005523,Parkinson Disease,MESH:D010300,0,,1,UP
"tryptophan 2,3-dioxygenase activity",GO:0004833,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
tubulin binding,GO:0015631,Parkinson Disease,MESH:D010300,0,,3,LRRK2|MAP2|PRKN
tubulin binding,GO:0015631,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
tubulin binding,GO:0015631,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
tubulin binding,GO:0015631,Parkinsonian Disorders,MESH:D020734,0,,3,DCTN1|LRRK2|PRKN
tumor necrosis factor receptor binding,GO:0005164,Parkinson Disease,MESH:D010300,0,,1,TNF
tyramine receptor activity,GO:0008226,Parkinsonian Disorders,MESH:D020734,0,,1,DOP1R2
tyrosine 3-monooxygenase activator activity,GO:0036470,Parkinson Disease,MESH:D010300,0,,1,PARK7
tyrosine 3-monooxygenase activator activity,GO:0036470,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
tyrosine 3-monooxygenase activator activity,GO:0036470,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
tyrosine 3-monooxygenase activity,GO:0004511,Parkinson Disease,MESH:D010300,0,,1,TH
tyrosine 3-monooxygenase activity,GO:0004511,Parkinsonian Disorders,MESH:D020734,0,,2,CAT-2|TH
tyrosine decarboxylase activity,GO:0004837,Parkinson Disease,MESH:D010300,1,Pyridoxine,0,
tyrosine decarboxylase activity,GO:0004837,"Parkinson Disease, Secondary",MESH:D010302,1,Pyridoxine,0,
ubiquinol-cytochrome-c reductase activity,GO:0008121,Parkinson Disease,MESH:D010300,5,4-phenylbutyric acid|Lead|Nitrites|Paraquat|Sirolimus,0,
ubiquinol-cytochrome-c reductase activity,GO:0008121,"Parkinson Disease, Secondary",MESH:D010302,4,3-methyladenine|Chlorpromazine|Haloperidol|Paraquat,0,
ubiquinol-cytochrome-c reductase activity,GO:0008121,Parkinsonian Disorders,MESH:D020734,7,Cadmium|Chlorpromazine|coenzyme Q10|Curcumin|Docosahexaenoic Acids|Haloperidol|Paraquat,0,
ubiquinol-cytochrome-c reductase activity,GO:0008121,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
ubiquitin binding,GO:0043130,Parkinson Disease,MESH:D010300,0,,1,PRKN
ubiquitin binding,GO:0043130,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
ubiquitin binding,GO:0043130,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
ubiquitin binding,GO:0043130,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
ubiquitin conjugating enzyme binding,GO:0031624,Parkinson Disease,MESH:D010300,0,,1,PRKN
ubiquitin conjugating enzyme binding,GO:0031624,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
ubiquitin conjugating enzyme binding,GO:0031624,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
ubiquitin ligase inhibitor activity,GO:1990948,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
ubiquitin ligase inhibitor activity,GO:1990948,Parkinsonian Disorders,MESH:D020734,0,,1,HTRA2
ubiquitin-like protein conjugating enzyme binding,GO:0044390,Parkinson Disease,MESH:D010300,0,,1,PARK7
ubiquitin-like protein conjugating enzyme binding,GO:0044390,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
ubiquitin-like protein conjugating enzyme binding,GO:0044390,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
ubiquitin protein ligase activity,GO:0061630,Parkinson Disease,MESH:D010300,0,,2,INS|PRKN
ubiquitin protein ligase activity,GO:0061630,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN2
ubiquitin protein ligase activity,GO:0061630,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
ubiquitin protein ligase activity,GO:0061630,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
ubiquitin protein ligase binding,GO:0031625,Parkinson Disease,MESH:D010300,0,,8,ABCB1|BAG5|DNM1L|HSPA1A|HSPA9|PINK1|PPARGC1A|PRKN
ubiquitin protein ligase binding,GO:0031625,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
ubiquitin protein ligase binding,GO:0031625,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
ubiquitin protein ligase binding,GO:0031625,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,ATXN3|SNCAIP
ubiquitin protein ligase binding,GO:0031625,"Parkinson Disease, Secondary",MESH:D010302,0,,2,ABCB1|PRKN
ubiquitin protein ligase binding,GO:0031625,Parkinsonian Disorders,MESH:D020734,0,,3,PARP1|PINK1|PRKN
ubiquitin-protein transferase activity,GO:0004842,Parkinson Disease,MESH:D010300,0,,1,PRKN
ubiquitin-protein transferase activity,GO:0004842,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
ubiquitin-protein transferase activity,GO:0004842,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
ubiquitin-protein transferase inhibitor activity,GO:0055105,Parkinson Disease,MESH:D010300,0,,1,PARK7
ubiquitin-protein transferase inhibitor activity,GO:0055105,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
ubiquitin-protein transferase inhibitor activity,GO:0055105,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
ubiquitin-specific protease binding,GO:1990381,Parkinson Disease,MESH:D010300,0,,2,PARK7|PRKN
ubiquitin-specific protease binding,GO:1990381,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
ubiquitin-specific protease binding,GO:1990381,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
ubiquitin-specific protease binding,GO:1990381,Parkinsonian Disorders,MESH:D020734,0,,2,PARK7|PRKN
unfolded protein binding,GO:0051082,Parkinson Disease,MESH:D010300,0,,4,CNX99A|HSC70-3|HSPA1A|HSPA9
unfolded protein binding,GO:0051082,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
unfolded protein binding,GO:0051082,Parkinsonian Disorders,MESH:D020734,0,,1,HTRA2
vascular endothelial growth factor receptor activity,GO:0005021,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
virus receptor activity,GO:0001618,Parkinson Disease,MESH:D010300,0,,2,HSPA1A|NECTIN2
voltage-gated calcium channel activity,GO:0005245,Parkinsonian Disorders,MESH:D020734,1,Diazoxide,0,
voltage-gated calcium channel activity involved in regulation of cytosolic calcium levels,GO:0099511,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
voltage-gated channel activity,GO:0022832,Parkinson Disease,MESH:D010300,1,Rotenone,0,
voltage-gated channel activity,GO:0022832,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
voltage-gated channel activity,GO:0022832,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
voltage-gated monoatomic ion channel activity,GO:0005244,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
voltage-gated monoatomic ion channel activity,GO:0005244,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
voltage-gated potassium channel activity,GO:0005249,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
voltage-gated potassium channel activity,GO:0005249,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
voltage-gated sodium channel activity,GO:0005248,Parkinson Disease,MESH:D010300,1,Estradiol,0,
wide pore channel activity,GO:0022829,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
xanthine oxidase activity,GO:0004855,Parkinson Disease,MESH:D010300,1,Zinc,0,
xanthine oxidase activity,GO:0004855,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
xenobiotic transmembrane transporter activity,GO:0042910,Parkinson Disease,MESH:D010300,0,,2,ABCB1|SLC18A2
xenobiotic transmembrane transporter activity,GO:0042910,"Parkinson Disease, Secondary",MESH:D010302,0,,2,ABCB1|SLC18A2
xenobiotic transmembrane transporter activity,GO:0042910,Parkinsonian Disorders,MESH:D020734,0,,1,SLC18A2
zinc ion binding,GO:0008270,Parkinson Disease,MESH:D010300,0,,10,ATP13A2|CNTNAP2|CPR|HSC70-3|MTA1|NOS1|PRKN|SNCA|SOD1|VPS35
zinc ion binding,GO:0008270,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
zinc ion binding,GO:0008270,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
zinc ion binding,GO:0008270,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
zinc ion binding,GO:0008270,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,3,ADH1C|ATXN2|NR4A2
zinc ion binding,GO:0008270,"Parkinson Disease, Secondary",MESH:D010302,0,,4,ATP13A2|PRKN|SHH|SNCA
zinc ion binding,GO:0008270,Parkinsonian Disorders,MESH:D020734,0,,5,ATP13A2|PARP1|PRKCD|PRKN|SNCA
zinc ion transmembrane transporter activity,GO:0005385,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
zinc ion transmembrane transporter activity,GO:0005385,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
zinc ion transmembrane transporter activity,GO:0005385,Parkinson Disease,MESH:D010300,0,,1,SLC30A10
zinc ion transmembrane transporter activity,GO:0005385,Parkinsonian Disorders,MESH:D020734,0,,1,SLC30A10
